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A comprehensive summary of the work to be incorporated in the thesis entitled
“STUDIES ON HETEROCYCLIC COMPOUNDS OF MEDICINAL INTEREST’’
included investigation pertaining to Benzo[b]thiophene ring system, derivatives of 3-
Isopropyl-4-methoxy benzaldehydes, Tetrahydropyrimidine derivatives and X-ray
crystallographic study which have been described as under:
[A] STUDIES ON BENZO[b]THIOPHENE DERIVATIVES
[B] STUDIES ON 3-ISOPROPYL-4-METHOXYBENZALDEHYDE DERIVATIVES
[C] STUDIES ON TETRAHYDROPYRIMIDINE DERIVATIVES
[D] X-RAY CRYSTALLOGRAPHIC STUDY
[A] STUDIES ON BENZO[b]THIOPHENE DERIVATIVES
Heterocyclic compounds bearing benzo[b]thiophene ring system and their
derivatives are demonstrates various biological and pharmacological activities. Our works
are paying attention on introduction of chemical multiplicity in the molecular frame work,
in order to synthesizing active molecules of widely different composition. Literature
assessment reveals that sulfur containing heterocyclic compounds have acknowledged
considerable attention in remedial science due to their biological and pharmacological
activities such as anti-HIV, antitubercular, antimicrobial, anticonvulsant, anticancer,
antiviral etc.
Considering the increasing importance of benzo[b]thiophene nucleus, we have
undertaken the synthesis of some new arylaminomethyl and oxadiazole derivatives bearing
benzo[b]thiophene nucleus, which have been described as under.
PART-I: STUDIES ON ARYLAMINOMETHYL DERIVATIVES
Arylaminomethyl derivatives represent one of the modest class of biological active
agents which have been deeply studied during search of new potential agents. These
have been reported to be active as antimicrobial, antitubercular, anticancer, insecticidal
etc. In view of these valid observations, it was contemplated to synthesize some new




SECTION-I: Synthesis and biological screening of (E)-N'-Arylmethine-5-bromo-
3-chlorobenzo[b]thiophene-2-carbohydrazides.
The azomethines of Type - (I) have been prepared by the condensation of 5-
bromo-3-chlorobenzo[b]thiophene-2-carbohydrazide with different aromatic aldehydes.










The compounds of Type - (II) have been synthesized by the reaction of arylamines
of Type - (I) with anhydrous NaBH4.
PART-II: STUDIES ON OXADIAZOLE DERIVATIVES
1,3,4-Oxadiazoles are associated with broad spectrum of pharmacological
activities like anesthetic, hypnotic, antibacterial, hypoglycemic, antifungal etc. These valid
observations prompted us to synthesize 1,3,4-oxadiazole derivatives with better






















The oxadiazole derivatives of Type - (III) have been synthesized by the
condensation of 5-bromo-3-chlorobenzo[b]thiophene-2-carbohydrazide with various
aromatic acids in the presence of POCl3.
[B] STUDIES ON 3-ISOPROPYL-4-METHOXYBENZALDEHYDE DERIVATIVES
Chalcones are phenylstyryl ketone containing reactive ethylinic group
(-COCH=CH-). Chalcone derivatives signify various biological activities such as
analgesic, anthelmintic, antiinflmmatory, antitubercular, antifungal, antimicrobial etc. Over
and above chalcones are very good synthons for various organic molecules. This valid
observation led us to synthesize some new chalcones, acetylpyrazoline and cyclohexenone
derivatives containing 3-isopropyl-4-methoxybenzaldehyde nucleus, which have been
described as under.







      Type – (IV)
The chalcone derivatives of Type - (IV) have prepared by the condensation of
















Pyrazolines of Type - (V) have been synthesized by the condensation of the
chalcones of Type - (IV) with hydrazine hydrate in glacial acetic acid.










Cyclohexenone derivat ives of  Type -  (VI)  have been prepared by
cyclocondensation of chalcones of Type - (IV) with ethyl acetoacetate in the presence
of basic catalyst K2CO3.
[C] STUDIES ON TETRAHYDROPYRIMIDINE DERIVATIVES
Pyrimidine nucleus possesses remarkable pharmaceutical importance and
biological activities, some of their derivatives occur as natural products, like nucleic
acids and vitamin B. Many pyrimidine derivatives have displayed diverse pharmacological
activities like antitumor, calcium channel blocker etc. In view of our on going interest in
the synthesis of substituted pyrimidines, the synthesis of some new potentially bioactive





SECTION-I: Synthesis and biological screening of N-(4-Chlorophenyl)-1,2,3,4-
tetrahydro-6-isopropyl-4-aryl-2-oxo/thioxopyrimidine-5-carboxamides using











     Type – (VII) X = O/S
Pyrimidine derivatives of Type (IV) have been prepared by the multicomponent
cyclization reaction of N-(4-Chlorophenyl)-4-methyl-3-oxopentanamide with urea/
thiourea and different aromatic aldehydes in the presence of molecular iodine.














Formylated tetrahydropyrimidines of Type - (VIII) have been prepared by the
formylation of different dihydropyrimidinones with DMF and POCl3.













  Type – (IX)
Formylated tetrahydropyrimidines of Type - (IX) have been prepared by the






[D] X-RAY CRYSTALLOGRAPHIC STUDY






Single crystal X-ray diffraction is the most common experimental method of
obtaining a detailed picture of a small molecule that allows resolution of individual atoms.
Single crystal of 1-Phenyl-3-methylpyrazole-2-en-5-one were grown by slow
evaporation technique at constant temperature using methanol as a solvent. Good quality
single crystals were harvested within 45 days.
The constitution of all the synthesized compounds have been characterized using
elemental analysis, FT-IR and 1H NMR spectroscopy and further supported by mass
spectroscopy. Purity of all the compounds have been checked by thin layer
chromatography.
All the compounds have been evaluated for their antibacterial activity towards
Gram +ve and Gram -ve bacterial strains and antifungal activity towards Aspergillus
niger at a concentration 40 μg/ml. The biological activities of the synthesized compounds







The chemistry of the heterocyclic compounds is as logical as that of aliphatic or
aromatic compounds. This study is of great interest both from the theoretical as well as
practical stand point. A heterocyclic compound is one which possesses acyclic structure
with at least one different kinds of atom other than carbon in the ring. The most common
type, contain largely nitrogen, oxygen and sulphur heteroatoms, but many other elements,
including even phosphorous, silicon can also serve. The heterocyclic compounds
containing the less common atoms have been subject to much investigation in recent
years.
The variety of heterocyclic compounds is enormous, their chemistry is complex
and synthesizing them requires great skill. Among large number of heterocycles found in
nature, nitrogen heterocycles are most abundant than those containing oxygen or sulphur
owing to their wide distribution in nucleic acid instant and involvement in almost every
physiological process of plants and animals.
Heterocyclic systems are encountered in many groups of organic compounds
possessing great applicability in industry as well as in our life in various ways i. e. most
of the sugars and their derivatives, including vitamin C, for instant, exist largely in the
form of five membered (Furanosied str.) or six membered (Pyranoised str.) ring containing
one oxygen atom. Most members of the vitamin B group possess heterocyclic rings
containing nitrogen; one example is vitamin B6 (Pyridoxine), which is a derivative of the
pyridine essential in amino acid metabolism. Many other examples of the importance of
heterocyclic compounds in biological systems can be given.
Natural products containing heterocyclic compounds such as alkaloids and
glycosides have been used since old age, as remedial agents. Febrifagl alkaloid from
ancient Chinese drug, Chang Shan, Reserpine from Indian rouwopifia, Curen alkaloid
from arrow poison, Codenine, j-Tropine and Strychnine are all examples of heterocyclic
compounds. Many antibiotics including penicillin, cephalosporin, norfloxacin,
streptomycin etc. also contain heterocyclic ring systems. Majority of the large number
of drugs being introduced in pharmacopeias in recent years are heterocyclic compounds.
Many veterinary products like Pyrantel and Morantel are the drug of choice as
broad spectrum anthelmintics. The herbicides Atrazine and Simazine are well known
8Studies on heterocyclic...
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example of heterocyclic agrochemicals. Plant pigments such as indigo, hemoglobin and
anthiocyanins, chlorophyll has contributed much colour chemistry and many other
heterocyclic colouring matters are in use since prehistoric times. The heterocyclic
Tetraselena fulvalene was the first ionic molecular crystal to demonstrate
superconductivity.
The word drug is derived from the French word drogue which means a dry
herb. According to WHO a drug may be defined as Any substance or product which is
used or intended to be used for modifying or exploring physiological system or
pathological status for the benefit of recipient.
There are two main divisions of medicinal chemistry. The first chemotherapy,
concerns the treatment of infections, parasite or malignant disease by chemical agents,
usually substances that show selective toxicity towards the pathogen. The other division
relates to diseases of body disfunction and the agents employed are mainly compounds
that effect the functioning of enzymes, the transmission of impulses or the action of
hormones on receptors. Heterocyclic compounds are used for all these purposes; because
they have a specific chemical reactivity. The introduction of heterocyclic group into drugs
may effect their physical properties, for example the dissociation constants of sulpha
drugs or modify their patterns of absorption, metabolism or toxicity.
During the period of 1930-1950 there was an urgent need for new drug to treat
disease which had a high mortality rate, there was only limited appreciation of the hazard
such drugs might present, and toxicological studies before clinical trials were fairly
rudimentary. Proving the proverb Necessity is the mother of invention, during the
decade of 30 and 40s a large number of drugs introduced. Therefore this peroid is
regarded as Golden Period of new drug discovery.
Heterocyclic compounds are obtainable by the following methods.
a. Isolation from natural sources, i.e. alkaloids, amino acids, indigo dyes etc.
b. Degradation of natural products i.e. acridine, furfural, indol, pyridine, quinoline,
thiophene etc.
c. Synthesis: Synthesis methods for obtaining heterocyclic compounds may be
divided into ring closer reactions, addition reaction and replacement reaction.
Cyclisation is usually accomplished by elimination of some small molecules such
as water or ammonia from chain of suitable length.
9Studies on heterocyclic...
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Heterocyclic compounds have a great applicability as drugs because,
a. They have a specific chemical reactivity.
b. They resemble essential metabolism and can provide false synthons in biosynthetic
process.
The current interest in the creation of large, searchable libraries of organic
compounds has captured an imagination of organic chemists and the drug discovery
community. Efforts in numerous laboratories focused on the introduction of chemical
diversity have been recently reviewed and pharmacologically interesting compounds have
been identified for libraries of widely different compositions.
Research in the field of pharmaceutical has its most important task in the
development of new and better drugs and their successful introduction into clinical
practice. Central to these efforts, accordingly stand the search for pharmaceutical
substances and preparation which are new and original. In addition to these objectives
the searching for drug which exhibit a clear advantage over a drug already known. Such
advantages may be qualitative or quantitative improvement in activity, the absence of
undesirable side effect, a lower toxicity, improved stability or decreased cost.
It is important at the outset to note that drug discovery is not an unambiguous
term in the pharmaceutical R and D world. For example, it can be defined using either
programmatic or organizational approaches (or both), with several options on each
category. Hence, it is important first to understand this variability and to adopt a specific
definition for the purpose of this discussion.
The contribution of organic chemistry to be development of scientific medicine in
the 19th century mainly from acyclic and carbocyclic compounds, although the pyrazoline
antipyrin 1 was introduced as an antipyretic and analgesic in 1984 and the first barbiturate
baritone (veranol) 2 in 1903. Guttmann treated, malaria with methylene blue in 1891,
with slight success, and in 1912 he introduced acriflavine as trypancide, it has proved to
be more valuable as an antiseptic. Phenazopyridini (pyridium) 3 was introduced for the
same purpose in 1926, and although it is relatively ineffective it has continued to be used




Taking in view of the applicability of heterocyclic compounds, we have undertaken
the preparation of heterocycles bearing benzo[b]thiophene, 3-isopropyl-4-
methoxybenzaldehyde and dihydropyrimidines nucleus. The placements of a wide variety
of substituents on these nuclei have been designed in order to evaluate the synthesized
products for their pharmacological profile against selected strains of bacteria and fungi.
During the course of our work, looking to the application of heterocyclic
compounds, several entities have been designed, generated and characterized using
spectral studies. The details are as under.
1. To generate several derivatives of benzo[b]thiophene and their fused derivatives
such as arylaminomethyl derivatives like Schiff’s base and it’s reduction,
oxadiazoles etc.
2. To generate chalcones, acetyl pyrazoline and cyclohexenone containing 3-
isopropyl-4-methoxybenzaldehyde as a basic core.
3. To synthesize several derivatives of oxo/thiopyrimidines under classical  biginelli
condition and catalytical method like molecular iodine as a catalyst at ambient
temperature and develope their 3-formyl derivatives.
4. To check purity of all synthesized compounds using thin layer chromatography.
5. To characterize these synthesized products for structure elucidation using various
spectroscopic techniques like IR, 1H NMR, mass spectral studies and C, H, N
analysis.
6. To grow single crystal of the synthesized compounds and study there X-ray
crystallograpy for establishment of the structure.
7. To evaluate these new synthesized products for better drug potential against
different strains of bacteria and fungi.



















Benzo[b]thiophene and its derivatives are important heterocycles which find uses
in pharmaceuticals, pesticides and in general organic synthesis1. Sulphur containing crude
petroleum is the main source of these compounds. However, separation of these
compounds from crude petroleum is a tedious process and hence the demand for these
compounds is mainly met by synthetic methods. A major stimulus to the study of
benzothiophene chemistry was the discovery of their importance in dye industry. 2-
Benzo[b]thiophene-2’-indoleindigo (1) and its substituted derivatives are useful class of
dyes and it was reviewed by Hartough and Meisel2.
Benzo[b]thiophene has also attracted interest as potential biological active agents.
It may serve as bioisosteres of indoles. Numerous benzo[b]thiophene analogs of
biologically active indole derivatives have proved to be agonists as antagonists of their
indole congeners, it was reviewed in detail by T. R. Bosin3 and E. Campaigne4. The
chemistry of benzo[b]thiophene (2) and benzo[c]thiophene (3) were reviewed by R. M.
Scrowston5 and B. Iodone6.
SYNTHETIC ASPECT
Various methods for the preparation of benzo[b]thiophene derivatives have been












( 2 ) ( 3 )
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1. C. Mukherjee and workers7 have synthesized benzo[b]thiophene derivatives using
direct metalation approach in synthesis.
2. o-Bromoethynylbenzene with S8 and NaBH4 in ethanol
8 can be converted into
bezo[b]thiophene.
3. Substituted acetophenones to benzo[b]thiophene conversation also possible with
t-BuOK in DMSO9 but the yield of the product is 23 %.
4. M. E. Borai et al.10 have been developed benzo[b]thiophene derivative from the
thiophene-2,3-dicarbaldehyde as a starting material.
5. M. G. Reinecke and co workers11 have been synthesized the benzo[b]thiophene































6. Synthesis of benzo[b]thiophene was carried out using AlPO4 and Pd/AlPO4 as a
catalyst12 from the 2-(phenylthio)ethanol.
7. Synthesis of benzo[b]thiophene from carboxylic acids and ketones was reported
by T. Higa et al.13 with 77 % yield.
8. C. M. Bonnin and co workers14 have synthesized benzo[b]thiophene derivatives
from alkoxy-substituted phenylpropiolic acids and esters with 72 % yield.














































10. Syntheses of dimethoxy and trimethoxy benzo[b]thiophene derivatives have been
achieved by J. G. Stuart et al.16 with good yield in two steps.
11. α-Halo,β-arylpropanoicacid can be converted in benzo[b]thiophene.17
12. Recently E. S. H. El Ashry et al.18 reported microwave assisted synthesis of
benzo[b]thiophene derivatives in short reaction time with improved 82 % yield.
13. A. H. K. Sharba et al.19 reported synthesis of hydrazide from benzo[b]thiophene-
2-acid chloride in chloroform with 73 % of yield.
14. Microwave assisted synthesis of benzo[b]thiophene hydrazide was reported by




























































Although the preparation of acid chlorides from carboxylic acids with thionyl
chlorides is a well-known and commonly used method, this reaction is of particular interest
as it includes the sulfur from the thionyl chloride in the final benzo[b]thiophene product21.
This reaction, although taking place through a multi-step pathway, is a single pot, relatively
high-yielding reaction, which proceeds smoothly to the final cyclized product.
The proposed reaction mechanism for the formation of benzo[b]thiophene.
THERAPEUTIC IMPORTANCE
Over recent years there has been an increasing interest in the chemistry of











































C. Routledge et al.52 have prepared benzo[b]thiophene (4) and it’s derivatives
and evaluated for their anticonvulsant activity.
D. J. Sall et al.53 have prepared diamino benzo[b]thiophene (5) and it’s derivatives
as a active site directed thrombin inhibitors.
Kuanuniamine A (6) is the simplest member of a group of marine alkaloids which
show strong antitumor activity in vivo and in vitro. They also exhibit immunosuppressive
and antiviral properties. W. F. Reynolds et al.54 has prepared compound 4,7-
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Benzo[b]thiophene derivatives...
A. Monge et al.55 have prepared benzo[b]thiophene derivatives (8)  and reported
their high affinity at the serotonin transporter and at 5-HT1A receptors.
J. A. Valderrama et al.56 have prepared benzo[b]thiophenes (9, 10) and their
application of benzo[b]thiophenequinones and naphthothiophenequinones with ortho-
amino functional on the thiophene ring possess a variety of biological properties against
human-T-cell leukemia virus (HTLV-1).
S. Brian et al.57 have prepared 3-benzylbenzo[b]thiophenes (11) which are
useful for treating diseases associated with post-menopausal syndrome, i.e. cancer of
the breast, uterus and cervix.
H. Lee et al.60 have synthesized benzo[b]thiophenes derivatives (12) and evaluated
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3  R = H
4  R = Ac







R6 R1 = OH, OCO(alkyl), OCO(aryl)
R2 = aryl, alkyl, cycloalkyl
R3 = O(CH2)2, O(CH2)3
R4 ,R5 = CO(CH2)2Me, CO(CH2)3Me, alkyl






1 R  =  H, F
R1= 1-Naphthyl, 2-Quinolyl,
         3-Quinolyl, 4-Quinolyl,











M. B. Sporn et al.58 have synthesized benzo[b]thiophenes (13) and it’s derivative
and testing for its antibreast cancer activity.
S. Yous et al.59 have synthesized and evaluated four novel benzo[b]thiophenes
derivatives (14) designed as Serotonin N-acetyltransferase (AANAT) inhibitors. Specific
AANAT inhibitors could be useful for treatment of different physiopathological disorders
encountered in diseases such as seasonal affective disorders or obesity.
K. Z. Grace et al.61 have synthesized benzo[b]thieno[2,3-c]quinolones (15, 16)















R1 = H, CH3, OCH3, COOCH3, 
        Br, CN 
R  = H, CH3, OCH3, COOCH3, F, NO2 













W. W. Wardakhan et al.62 have synthesized 2-aminothiophene-3-carboxamide
derivatives (17) and evaluated for their antimicrobial activity against gram-positive and
gram-negative bacteria.
M. S. Malamas and coworkers63 have synthesized novel benzothiophene
derivatives inhibitors of protein tyrosine phosphatase 1B with antihyperglycemic
properties. S. S. Perez et al.64 developed 5-substituted benzo[b]thiophene derivatives
with dual action at 5-HT1A serotonin receptors and serotonin transporter as a new class
of antidepressants. Synthesis and serotonergic activity of benzothiophene-4-piperazine
derivatives as novel antagonists for the vascular 5-HT1B receptor has been achieved by
G. P. Moloney and group65.  S. Galiano et al.66 synthesized thiophene and
benzo[b]thiophene hydrazide derivatives and reported them as human NPY Y5
antagonists. Inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II,
and IX with benzo[b]thiophene 1,1-dioxide sulfonamides have been reported by A.
Innocenti and coworkers67. I. Jarak and coworkers68 synthesized, novel cyano and N-
isopropylamidino-substituted derivatives of benzo[b]thiophene-2-carboxanilides and
reported antitumor activity.
B. Peschke et al.69 have reported benzo[b]thiophene-2-carboxamides as potent
antagonists of the human H3-receptor. New HIV-1 reverse transcriptase inhibitors based
on a tricyclic benzothiophene scaffold has been reported by K. Krajewski et al.70 D. J.
Witter et al.71 have discovers benzo[b]thiophene based histone deacetylase inhibitors
and report it as anti-proliferative. Synthesis of 2 and 3-aminobenzo[b]thiophene
derivatives as antimitotic agents and inhibitors of tubulin polymerization have been
reported by R. Romagnoli and coworkers.72 A. J. Li et al.73 reported synthesis and
evaluation for dual 5-HT1A/SSRI activities of benzo[b]thiophene derivatives. Synthesis
and cannabinoid activity of a variety of 2,3-substituted 1-benzo[b]thiophen derivatives










Derivatives of benzo[b]thiophene are also available as drug, some of them are
shown as under:
Work done from our laboratory
V. V. Kachhadia synthesized 6-Carbethoxy-5-aryl-3-[p-(3'-chloro-2'-
benzo[b]thiophenoylamino)phenyl]-2-cyclohexenones (18)75, heterocyclic systems
containing S/N regioselective nucleophilic competition like, thiohydantoins and
thiazolidinones (19)76  derivatives  bearing benzo[b]thiophene nucleus and reported their
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Benzo[b]thiophene derivatives...
S. L. Vasoya reported facile synthesis of some new azetidinones and acetyl
oxadiazoles as a potent biological active agent77, thiosemicarbazides and 1,3,4-
thiadiazoles (20) as potent antitubercular and antimicrobial agents78, thiosemicarbazide
and 1,2,4-triazoles (21) heterocycles as a potent antitubercular and antimicrobial agents79
bearing benzo[b]thiophene nucleus.
K. M. Thaker synthesized and reported pharmacological evaluation of 1,3,4-
thiadiazoles80, imidazolones (22) and 1,2,4-triazoles as antimicrobial agents81, thiourea
derivatives as potential antimicrobial agents82, 1,3,4-oxadiazoles (23) and 2-
arylsulfonylhydrazinocarbonyl-3,5-dichlorobenzo[b]thiophenes and its pharmacological
evaluation83.
In view of procuring highly potent biodynamic agents after this literature survey
and on continuation of our on going work on benzo[b]thiophenes for their various methods
of synthesis and different biological activities, synthesis of benzo[b]thiophene have been
undertaken in order to achieve superior therapeutic agents. This can be summarized in
the following sections as under.
STUDIES ON BENZO[b]THIOPHENE DERIVATIVES
PART-I: STUDIES ON ARYLAMINOMETHYL DERIVATIVES
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Azomethine derivatives have been found to be potent drug in pharmaceutical
industries and possess a wide spectrum of biological activity. Azomethines are also known
as Schiff’s base and they are well known intermediate for the preparation of azetidinone,
thiazolidinone, formazone, aryl acetamide and many other derivatives. These are the
compounds contain characteristic -C=N group. B. S. Holla et al.1 have documented
azomethines (1) having triazole moiety and possess good antibacterial activity.
Azomethines are obtained mainly by warming the aldehyde and aromatic amine
together. However, it is more convenient to work in a solvent such as alcohol, dilute
acetic acid or glacial acetic acid. Some time the reaction is aided by trace of acid in
other cases the hydrochloride of the amines can be used in the synthesis.
In general Schiff’s bases do not react further with either of the reagents used in
their preparation as do most of the other types of simple intermediates.
SYNTHETIC ASPECT
Various methods for the preparation of azomethine derivatives have been cited in
literature, some of the methods are as under.
1. General account of the summary of reaction of aldehydes with amine (aromatic
or aliphatic) has been reviewed by Murray2.
2. E. C. Creencia and group3 reported synthesis from ortho substituted aniline with


















3. D. Bleger et al.4 have synthesized Schiff’s base of aniline and benzaldehyde in
ethanol with short reaction time of 4 hours and reported E isomer as major
product.
4. U. K. Roy and coworkers5 have reported preparation of Schiff’s base with 100 %
of yield with toluene as a solvent.
5. L. B. Pierre and coworkers6 have synthesized (E)-N-phenyl methyleneglycine
ethyl ester by the cyclocondensation of glycine ethyl ester hydrochloride,
t-butylmethyl ether (TBME), benzaldehyde was added followed by anhydrous
Na2SO4 and triethylamine.
6. J. G. Amanda et al.7 have prepared Schiff bases by condensation of equimolar




































7. L. Somogyi8 reported some azomethine derivatives of phenylhydrazide in 99 %
yield and with short reaction time of 3.5 hours in polar solvent.
8. Schiff’s base of o-phenelene diamine with substituted benzaldehyde was reported
by M. Zintl and coworkers9.
THERAPEUTIC IMPORTANCE
Schiff’s bases exhibit a wide range of pharmacological activities like antifungal,
antibacterial, antiviral, anti-inflammatory etc. R. H. Mehta et al.10 have synthesized
coummarin Schiff’s base derivatives (2) and examined for their antibacterial activity. A.
K. Khalafallah and M. E. Hassan11 have prepared some styryl Schiff ’s bases spiro
derivatives as potential antibacterial and antifungal activity. P. Perumal12 have synthesized
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M. D. Deshmukh and A. G. Doshi13 prepared some new Schiff ’s bases show
good antimicrobial activity against test organism S. aureus, E. coli, Saigella dysenteridse
and Salmonella typhi. Wang et al.14 have synthesized diazomethines having good plant
hormone activity. Das Arima et al.15 have prepared Schiff’s bases of aminohydroxy
guanidine (SB-AHG5) and tested for antiviral activity against Herpes Simplex virus Type
I (HSV-1) and adenovirus Type-5 (Ad-5).
Ali yusuf et al.16 have synthesized some Schiff ’s base derivatives of glucose
containing acetylenic bond. The prepared Schiff bases were tested for their bactericidal
activity against E. coli and S. aureus.
B. S. Holla et al.17 have prepared Schiff ’s bases and reported them as
antimicrobial agents. Pandey Taruna et al.18 prepared azomethines and their boron
complexes and screened for their antifungal and antibacterial properties. It is evident
that azomethines along with quite toxic but their activity increased after complexation.
Omar et al.19 have determined cyclocondensation of azomethines having good
antischistosomal activity. Chohan and coworkers20,21 have synthesized a novel class of
acetyl ferrocene derived from Schiff’s bases possess antimicrobial activity. Some
azomethine derivative screened for various antibacterial strains.
Das Joydip et al.22 have synthesized trans-N-refinylidene-n-butylamine (4) which
found stabilized in liposome’s of phophatidylcholine. The rate of formation of the Schiff’s
base is found to decrease with increasing cholesterol concentration in the membrane. V.
M. Patel23 has synthesized some new Schiff’s bases having good antibacterial activity.
Ram Tilak et al.24 have synthesized some Schiff ’s bases, of 2-chloro
phenothiazines and screened against carrageenin-induced edema in albino rats.
A. Cascaval et al.25 have synthesized azomethines, which have good analgesic and
antipyretic properties. S. N. Pandeya et al.26 have synthesized Schiff’s bases showed
good activity against Vibrio cholerae non-o., Shigella boydii, Enterococcus faecalis






and Edwaredsiella torla with MIC in the rang of 10-25 ìg/ml. Some compounds were
found to be active against Salmonellal typhi and Vibro cholerae-0, (MIC 25-150 ìg/
ml).
K. N. Venugopal et al.27 have synthesized Schiff ’s base of 4-hydroxy-6-
carboxyhaydrazino benzothiophene analog with different substituted aldehydes and
determined pharmacological study. Ergenc and coworkers28 have synthesized azomethine
derivatives having antifungal activity. B. Yadav and S. S. Sangapure29 have synthesized
some azomethines and tested for their biological activity. B. S. Holla et al.30 have prepared
some new Schiff’s bases having anticancer activity.
R. V. Chambhare et al.31 have prepared some azomethines and tested for their
antimicrobial activity. M. S. Karthikeyan et al.32 have synthesized azomethines (5) having
antibacterial and anti-inflammatory activity.
Work done from our laboratory
Synthesis of schiff’s bases (6) bearing benzo[b]thiophene nucleus as potential
antitubercular and antimicrobial agents was developed by K. M. Thaker33. S. L. Vasoya34
reported facile synthesis of some new azomethines (7) bearing benzo[b]thiophene nucleus
as a potent biological active agent.
T. K. Dave have been reported synthesis and pharmacological study of Mannich
bases of 4-amino-3-mercapto-5-pyridin-3'-yl-[1,2,4]-triazole (8)35 and schiff’s base
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Looking to the interesting properties of azomethines, we have synthesized some
new azomethines, which have been described as under.
PART-I: STUDIES ON ARYLAMINOMETHYL DERIVATIVES
SECTION-I: SYNTHESIS AND BIOLOGICAL SCREENING OF (E)-N’-
ARYLMETHINE-5-BROMO-3-CHLOROBENZO[b]THIOPHENE-
2-CARBOHYDRAZIDES.

















SYNTHESIS AND BIOLOGICAL SCREENING OF (E)-N’-ARYLMETHINE-5-
BROMO-3-CHLOROBENZO[b]THIOPHENE-2-CARBOHYDRAZIDES.
The growing patent literature of recent years demonstrates that the azomethine
derivatives are used as better therapeutic agents. In view of these findings, it appeared
of interest to synthesize Schiff ’s base by the condensation of 5-bromo-3-
chlorobenzo[b]thiophene-2-carbohydrazide with various aromatic aldehydes in order
to study their biodynamic behavior.
The constitution of the synthesized compounds have been characterized by using
Elemental analysis, Infrared, 1H Nuclear Magnetic Resonance spectroscopy and further
supported by mass spectroscopy.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards A. Niger at a concentration of 40 μg/ml. The biological







































Melting points of all the synthesized compounds were taken in open capillary
bath on controlled temperature heating mental. The crystallization of all the compounds
was carried out in appropriate solvents. TLC was carried out on silica gel-G as stationary
phase. 20 % Ethyl acetate in Hexane was used as a mobile phase.
[A] Preparation of 3-bromocinnamicacid
Take 3-bromobenzaldehyde (1.85 gm, 0.01 mole) and anhydrous malonic acid
(2.5 gm, 0.025 mole) in 50ml RBF, to this add pyridine (10 ml). Dissolve all the content
and reflux it on oil bath for 4 hrs. at 110 °C Pour the content onto crushed ice, acidified
it with conc. HCl (pH = 4-5). Filter the solid mass under vacuo and crystallized from
methanol. Gives white to light yellow crystalline powder, Yield: 84 %, M.P.: 177-180 °C,
reported 178-182 °C.
[B] Preparation of 5-bromo-3-chlorobenzo[b]thiophene-2-carbonyl chloride
A mixture of 3-bromocinnamic acid (7.12 gm, 0.039 mole), thionyl chloride (20
ml) and pyridine (0.5 ml) was heated at 100 °C for 24 hrs. The excess of thionyl chloride
was distilled off. The content was poured into hot dioxane. The yellow crystalline product
so obtained was crystallized from Hexane. Yield: 75 %, M.P.: 102-104 °C, reported
101 °C.
[C] Preparation of 5-bromo-3-chlorobenzo[b]thiophene-2-carbohydrazide
A combination of 5-bromo-3-chlorobenzo[b]thiophene-2-carbonylchloride (3.1
gm, 0.01 mole) and hydrazine hydrate (1 gm, 0.02 mole) in methanol (25 ml) was heated
under refluxed condition for 6 hr. The solid obtained was filter and washed with water
under vacuo and the product so obtained was crystallized from dioxane. Yield: 72 %,
M.P.: 156 °C, Calc.C, 35.37%; H, 1.98%; N, 9.17% for C9H6BrClN2OS found C,
35.25%; H, 2.08%; N, 9.08%.
[D] General procedure for the preparation of (E)-N’-Arylmethine-5-bromo-3-
chlorobenzo[b]thiophene-2-carbohydrazides.
A mixture of 5-bromo-3-chlorobenzo[b]thiophene-2-carbohydrazide (1.53 gm,
0.005 mole) and arylaldehyde (0.005 M) in toluene (20 ml) was refluxed in presence of
glacial acetic acid in catalytic amount (0.5 ml) for 6 hr. with Dean Stark apparatus. The
solvent was removed under vacuo and the solid so isolated was crystallized from suitable
solvent. The physical constants of the product are recorded in Table-1a.
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SPECTRAL STUDY 























































































Instrument: Shimadzu FTIR-8400 using KBr DRS techniques. The percentage transmittance is 
given in cm-1 and frequency range is between 400-4000cm-1. 
  
Type Vibration Mode Frequency cm-1
Alkane -CH3
C-H str. (asym.) 2955
C-H str. (sym.) 2836
C-H str. (asym) 1484
C-H str. (sym) 1343
Aromatic
C-H str. 3061, 3170
C=C (skeleton) 1505, 1593
C-H  i.p. bending 1046
C-H o.p. bending 861
Amide -NH-C=O str. 1662
Amine -N-H str. 3289













1H NMR spectra of (E)-N’-(4-Methoxyphenyl)methine-5-bromo-3-chloro-
benzo[b]thiophene-2-carbohydrazide.




















of Protons Multiplicity Inference
J value
in Hz
1 3.86 3H singlet -OCH3 -
2 6.93-6.95 2H doublet Ar-Ha,a' 8.28
3 7.44-7.49 1H dd Ar-Hd 7.92, 3
4 7.61-7.65 1H doublet Ar-He 8.24
5 7.80-7.82 2H doublet Ar-Hb,b' 8.48
6 8.04-8.05 1H doublet Ar-Hc 3.92
7 8.37 1H singlet methine-H -















































































































































































































Biological screening of (E)-N’-Arylmethine-5-bromo-3-chlorobenzo[b]thiophene-
2-carbohydrazides.
Method : Cup-Plate37
Gram positive bacteria : Staphylococcus aureus ATCC 6538
  Staphylococcus epidermidis ATCC 12228
Gram negative bacteria : Escherichia coli ATCC 8739
  Pseudomonas aeruginosa ATCC 1539
Fungi : Aspergillus niger ATCC 16888
Concentration : 1000 μg/ml
Solvent : Dimethyl formamide (DMF)
Standard drugs : Amoxicillin, Ciprofloxacin, Cephalexin,
  Erythromycin, Griseofulvin
The antimicrobial activity was compared with standard drug viz Amoxicillin,
Ciprofloxacin, Cephalexin, Erythromycin and antifungal activity was compared with viz
Griseofulvin. The inhibition zones measured in mm.
(a) Antibacterial activity
The purified products were screened for their antibacterial activity using cup-
plate agar diffusion method. The nutrient agar broth prepared by the usual method was
dispensed in 50 ml quantities of different conical flasks. Then, add the 0.5 ml culture of
each bacteria (Staphylococcus aureus ATCC 6538, Staphylococcus epidermidis ATCC
12228, Escherichia coli ATCC 8739 and Pseudomonas aeruginosa ATCC 1539) in
nutrient agar broth and inoculate at 37°C for 24 hr.
The nutrient agar was melted at 100 °C and after cooling to 56 °C, was poured
into petri plates of 13 cm diameter in quantities of 20 ml, and left on a flat surface to
solidify and the surface of the medium was dried at 37 °C. Then, above subcultures of
each bacteria pipetted in to the nutrient agar plate. The cups (10 mm diameter) were
formed by the help of borer in agar medium and filled with 0.04 ml (40 μg) solution of
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sample in DMF. The plates were incubated at 37 °C for 24 hr and the control was also
maintained with 0.04 ml of DMF in a similar manner. After the completion of incubation
period, the zone of inhibition of growth in the form of diameter in mm was measure and
recorded in Table-1b.
(b) Antifungal activity
Aspergillus niger ATCC 16888 was employed for testing antifungal activity using
cup-plate agar diffusion method. The culture was maintained on sabourauds agar slants,
sterilized sabourauds agar medium was inoculated with 72 hr. old 0.5 ml suspension of
fungal spores in a separate flask.
The sabourauds agar was melted at 100 °C and after cooling to 56 °C, was
poured into petri plates of 13 cm diameter in quantities of 20 ml, and left on a flat
surface to solidify and the surface of the medium was dried at 37 °C. Then, above
subculture of fungi pipetted in to the sabourauds agar plate. The cups (10 mm diameter)
were formed by the help of borer in agar medium and filled with 0.04 ml (40 μg) solution
of sample in DMF. The plates were incubated at 30 °C for 48 hr. and the control was
also maintained with 0.04 ml of DMF in a similar manner. After the completion of
incubation period, the zone of inhibition of growth in the form of diameter in mm was






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































SYNTHESIS AND BIOLOGICAL SCREENING OF N’-ARYLMETHYL-5-
BROMO-3-CHLOROBENZO[b]THIOPHENE-2-CARBOHYDRAZIDES.
Aminomethyl derivatives of heterocyclic compounds are associated with diverse
biological activities. These finding prompted us to synthesize some representative
aminomethyl derivative bearing benzo[b]thiophene moiety obtained by selective reduction
of (imine group) Schiff’s bases with sodium borohydride in controlled experimental
condition as shown in the reaction scheme.
The constitution of the synthesized compounds have been characterized by using
Elemental analysis, Infrared, 1H Nuclear Magnetic Resonance spectroscopy and further
supported by mass spectroscopy.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards A. niger at a concentration of 40 μg/ml. The biological activities



















Melting points of all the synthesized compounds were taken in open capillary
bath on controlled temperature heating mental. The crystallization of all the compounds
was carried out in appropriate solvents. TLC was carried out on silica gel-G as stationary
phase. 10 % Ethyl acetate in Hexane was used as a mobile phase.
[A] General procedure for the preparation of (E)-N’-Arylmethine-5-bromo-3-
chlorobenzo[b]thiophene-2-carbohydrazides.
See, Part-A, Part-1, Section-I Experimental Section [D].
[B] General procedure for the preparation of N’-Arylmethyl-5-bromo-3-
chlorobenzo[b]thiophene-2-carbohydrazides.
To a  (E ) -N’ -ary lmethine-5-bromo-3-chlorobenzo[b ] th iophene-2-
carbohydrazides (0.01 mole) in tetrahydrofuran (25 ml), sodium borohydride (0.57 gm,
0.15 mole) was added over a period of  30 minutes at temperature 5-10 oC. The reaction
mixture was then stirr for 3 hours at room temp. After adding water the product was
extracted with ether. The ether extract was washed with water until neutral, then dried
over anhydrous Na2SO4 and finally the ether was evaporated to give solid product. The
physical constants of the product are recorded in Table-2a.
[C] Biological screening of N’-Arylmethyl-5-bromo-3-chlorobenzo[b]thiophene-
2-carbohydrazides.
Antimicrobial testing was carried out as described in Part-A, Part-1, Section-I,
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Instrument: Shimadzu FTIR-8400 using KBr DRS techniques. The percentage transmittance is 
given in cm-1 and frequency range is between 400-4000cm-1. 
Type Vibration Mode Frequency cm-1
Alkane -CH3
C-H str. (asym.) 2918
C-H str. (sym.) 2850
C-H i.p.d (asym) 1465




C-H  i.p. bending 1087
C-H o.p bending 840
Amide -NH-NH-C=O str. 1665












1H NMR spectra of N’-(4-Methoxyphenyl)methyl-5-bromo-3-chlorobenzo[b]-
thiophene-2-carbohydrazide.




















of Protons M ultiplicity Inference
J value
in Hz
1 3.78 3H singlet -OCH3 -
2 4.02 2H singlet -N-CH2-Ar -
3 6.86-6.88 2H doublet Ar-Hb,b' 8.52
4 7.33-7.35 2H doublet Ar-Ha,a' 8.52
5 7.43-7.47 1H triplet Ar-Hd 7.88
6 7.69-7.71 1H doublet Ar-Hc 7.6
7 7.87-7.85 1H doublet Ar-He 8.08
8 7.93 1H singlet(b) -NH -
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Oxadiazoles belong to an important group of heterocyclic compounds having a
toxophoric –N=C-O- linkage. It is well doccumented that oxadiazole system contains
the following members which are numbered by designating the hetero atoms at particular
position.
1,3,4-Oxadiazole is a heterocyclic molecule with oxygen atom at 1 and two
nitrogen atoms at 3 and 4 position. 1,3,4-Oxadiazole is a thermally stable aromatic
molecule1. They have been known for about 80 years it is only in the last decade that
investigations in this field have been intensified. This is because of large number of
applications of 1,3,4-oxadiazoles in the most diverse areas viz. drug synthesis, dye stuff
industry, heat resistant materials, heat resistant polymers and scintillators, reviews of the
relevant literature prior to 1965 are available2.
SYNTHETIC ASPECT
Most 1,3,4-oxadiazoles are best obtained by synthesis from acyclic precursors.
Such reactions are ‘one bond’ or ‘two bond’ cyclization. Different methods for the
synthesis have been cited in literature.3-8
1. Hansong Chen et al.9 have synthesized oxadiazoles by the reaction of hydrazide
and aromatic acid in presence of POCl3.
2. D. Ramesh and B. Sreenivasan10 have synthesized 1,3,4-oxadiazoles from






























3. K. Mogilaiah and B. Sakram11 have prepared 1,3,4-oxadiazoles from
acetophenone-2-trifluoromethyl-1,8-naphthyridine-3-carbonylhydrazone in the
presence of acetic anhydride.
4. Yu Yuve have reported microwave assisted synthesis protocol with 91 % of the
yield12.
5. L. Somogyi13 synthesized 1,3,4-oxadiazoles from several steps, from aryl
hydrazide and aryl aldehyde.
6. Silica coated with sulfuric acid as a catalyst used for the rapid and ecofriendly


































































7. Green chemistry and one-pot, solvent-free using microwave mediated synthesis
of 1,3,4-oxadiazoles were reported by V. Polshettiwar15
THERAPEUTIC IMPORTANCE
2,5-Disubstituted-1,3,4-oxadiazole derivatives have been tested for various











11. Hypnotic and sedative26
12. MAO inhibitor27
13. Insecticidal28
Some 1,3,4-oxadiazoles possessing insecticidal activity were synthesized by
Xiumian Zheng et al.29 Takahiko Inoue et al.30 have reported oxadiazoles useful as prolyl
aminopeptidase inhibitor. H. Liszkiewicz. et al.31 have screened oxadiazoles for their
antimicrobial activity.
Virginija Jakubkiene et al.32 have screened 1,3,4-oxadiazoles for their
antiinflammatory activity. Song Cao et al.33 have investigated some oxadiazoles possessing
insecticidal activity. S. Guniz Kucukguzel et al.34 have discovered oxadiazole derivatives
and reported their antimycobacterial activity. Ali Almasired et al.35 have prepared 1,3,4-
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oxadiazoles (5) as anticonvulsant agent. Meria Grazia Mamolo et al.36 have synthesized
3-substituted-5-(pyridine-4-yl)-3H-1,3,4-oxadiazole-2-one (6) and studied their
antimycobacterial activity.
Sahin G. et al.37 have reported antimicrobial activity of oxadiazole derivatives.
Maslat A. O. et al.38 have documented antibacterial, antifungal and genotixic activity of
bis-1,3,4-oxadiazole derivatives. Mida Malvina Buruliene et al.39 have investigated some
oxadiazoles as anti-inflammatory agents. K. Subrahmanya Bhat et al.40 have prepared
new fluorine containing 1,3,4-oxadiazoles (7) and reported them as potential antibacterial
and anticancer agents. T. P. Mohan et al.41 have synthesized 2,5-disubstituted-1,3,4-
oxadiazole derivatives (8) and screened for their insecticidal activity.
Recently, Ronald Kim et al.42 have discovered oxadiazole derivatives useful as
protease inhibitors. Mohd Amir and Kumar Shikha43 have documented antiinflammatory,
analgesic and ulserogenic activity of some newly synthesized oxadiazoles. Ali A. et al.44
have investigated some oxadiazole derivatives possessing antimicrobial and anti-HIV -
1-activity. Sherif A. et al.45 have reported oxadiazoles as potential antitumor and anti-
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1,3,4-oxadiazoles (9) possessing anticonvulsant activity. Mahamud Tareq et al.47 have
synthesized 2,5-disubstituted-1,3,4-oxadiazoles (10) useful as tyrosinase inhibitors.
Work done from our laboratory
Synthesis and pharmacological evaluation of 2-(3',5'-dichlorobenzo[b]thiophen-
2'-yl)-5-aryl-1,3,4-oxadiazoles (11) were reported by K. M. Thaker48.
Thus with an effort to capitalize the biological potential of the heterocyclic system
and to provide more interesting compounds for biological screening, we have under
taken the synthesis of several oxadiazoles which has been described as under.
























SYNTHESIS AND BIOLOGICAL SCREENING OF 2-(5-BROMO-3-
CHLOROBENZO[b]THIOPHEN-2-YL)-5-ARYL-1,3,4-OXADIAZOLES.
Synthesis of 1,3,4-oxadiazole derivatives has attracted considerable attention in
view of therapeutic applications. Looking to this, the synthesis of 1,3,4-oxadiazoles
was undertaken by the condensation of different aromatic acid with 5-bromo-3-
chlorobenzo[b]thiophene-2-carbohydrazide in presence of phosphorous oxychloride,
as shown in Reaction Scheme.
The constitution of the synthesized compounds have been characterized by using
Elemental analysis, Infrared, 1H Nuclear Magnetic Resonance spectroscopy and further
supported by mass spectroscopy.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards A. Niger at a concentration of 40 μg/ml. The biological
















Melting points of all the synthesized compounds were taken in open capillary
bath on controlled temperature heating mental. The crystallization of all the compounds
was carried out in appropriate solvents. TLC was carried out on silica gel-G as stationary
phase. 40 % Ethyl acetate in Hexane was used as a mobile phase.
[A] Preparation of 5-Bromo-3-chlorobenzo[b]thiophene-2-carbohydrazide
See, Part-A, Part-1, Section-I, Experimental section [C].
[B] General procedure for the preparation of 2-(5-Bromo-3-chlorobenzo[b]-
thiophen-2-yl)-5-aryl-1,3,4-oxadiazoles.
A mixture of 5-bromo-3-chlorobenzo[b]thiophene-2-carbohydrazide (1.53 gm,
0.005 mole) and substituted benzoic acid (0.005 mole) in phosphorous oxychloride (10
ml) was refluxed for 6 hr on oil bath. The content was cooled, poured onto crushed ice
and neutralized with sodium bicarbonate solution. Separated solid were filter and dried
in vacuo. Crude product was isolated and crystallized from suitable solvent to give
analytically pure product. The physical constants of the product are recorded in
Table-3a.
[C] Biological screening of 2-(5-Bromo-3-chlorobenzo[b]thiophen-2-yl)-5-aryl-
1,3,4-oxadiazoles.
Antimicrobial testing was carried out as described in Part-A, Part-1, Section-I,
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Instrument: Shimadzu FTIR-8400 using KBr DRS techniques. The percentage transmittance is 
given in cm-1 and frequency range is between 400-4000cm-1. 
Type Vibration Mode Frequency cm-1
Alkane -CH3
C-H str. (asym.) 2950
C-H str. (sym.) 2849
C-H i.p.d (asym) 1440
C-H o.o.d (sym) 1306
Aromatic
C-H str. 3013
C=C (skeleton) 1493, 1588
C-H  i.p. bending 1176

















1H NMR spectra of 2-(5-Bromo-3-chlorobenzo[b]thiophen-2-yl)-5-(4-methoxy-
phenyl)-1,3,4-oxadiazole.







of Protons Multiplicity Inference
J value
in Hz
1 3.91 3H singlet -OCH3 -
2 7.09-7.11 2H dd Ar-Ha,a' 8.02 & 0.9
3 7.50-7.53 1H triplet Ar-Hd 7.88
4 7.89-7.92 1H doublet Ar-He 8.72
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The term Chalcone was first coined by Kostanecki and Tambor1, who did
pioneering work in the synthesis of natural coloring compounds. The chemistry of
chalcones has generated intensive precise studies all over the world, especially interesting
for their biological and industrial applications. Chalcones are colored compounds because
of the presence of the chromophore and auxochromes. They are known as
benzalacetophenones or benzylidene acetophenones.
Chalcones (1) are characterized by their possession of a structure in which two
aromatic rings are linked by an aliphatic three carbon chain.
The chalcones were known from different names like phenyl styryl ketones,




A significant variety of methods are existing in literature for the synthesis of
chalcones. The most convenient way is the Claisen-Schmidt condensation which involves
aryl methyl ketones condensed with aryl aldehyde in presence of alcoholic alkali2.
Alternative synthetic routes for better yield, shorter reaction time to synthesize
new analogs
Various modifications have been applied to Claisen-Schmidt condensation to get
better yield and to synthesize biologically active analogs. Different catalysts have been
reported to increase the yield of the reaction. Microwave synthesis strategies have also
applied to shorten the reaction time. Solid phase synthesis and combinatorial chemistry







During the past two decades, combinatorial chemistry has appeared as one of
the most valuable tools used to accelerate drug discovery and lead optimization processes.
The emergence of this new field has promoted the transfer of solution-phase functional
group transformations to the solid phase.
A. R. Katritzky and coworker have synthesized chalcone derivatives by using
sodium methoxide as a catalyst and Wang resin as a solid support3. Jian Cao and group
reported polymer-supported selenium-induced solid - phase   synthesis4. Kamal Ahmed
et al. demonstrated solid-phase synthetic protocol for the chalcone and its derivatives5.
 Liquid-Phase Synthesis
In the solid phase synthesis there are some disadvantages of this methodology
compared to standard solution-phase synthesis, such as difficulties to monitor reaction
progress, the large excess of reagents typically used in solid-phase supported synthesis,
low loading capacity and limited solubility during the reaction progress and the
heterogeneous reaction condition with solid phase6.
S. Yongjia et al. reported soluble polymer-supported synthesis of chalcone
derivatives7. Saravanamurugan and coworker used ZSM-5 catalyst and Liquid   phase
synthesis strategy for the derivative preparation8. E. V. Stoyanov and group demonstrated
liquid phase synthesis of 2'-hydroxychalcone derivatives9.
Microwave Assisted Synthesis
Microwave irradiation (MWI) has become an established tool in organic synthesis,
because of the rate enhancements, higher yields and often, improved selectivity with
respect to conventional reaction conditions10.
In recent years, solvent free reactions using either organic or inorganic solid
supports have received increasing attention. K. Mogilaiah and coworker describe
synthesis of chalcones with p-toluene sulphonic acid (PTSA) as a catalyst under
microwave irradiation and solvent free conditions11, S. Katade et al. reported the synthesis
of chalcones with microwave irradiation and reported the reaction time decreases and





The other catalysts employed in synthesis and some time with advantages are
alkali of different strength13,14, hydrochloric acid15,16, phosphorous oxychloride17,
piperidine18, anhydrous aluminium chloride19, boron trifluoride20, amino acids21, perchloric
acid22 etc. S. Ryo and group reported synthesis using ruthenium as a catalyst and get
better yield23.
Chalcones can also be synthesized by condensing several other reagents instead
of an aldehyde and ketone.
1. Nencki reaction with cinnamic acid on an aromatic compounds24.
2. Diazo coupling of phenyl diazonium chloride with benzoyl acrylic acid25.
3. Friedel craft’s cinnamoylation26.
4. Fries rearrangement of aryl cinnamates27.
REACTION MECHANISM




Two alternative mechanisms were advanced for the reaction of benzaldehyde



















































The intermediate aldol type products formed readily undergoes dehydration even under
mild condition, particularly when R and R’ are aryl groups.
(B) Acid catalyzed:
The formation of chalcones by the acid catalyzed condensation of acetophenones
and aldehydes has been studied29. The rate of reaction depends on the first power of the
concentration of aldehyde and the Hammet acidity function. Also the condensation step
has been shown to be the rate determining step in this reaction. The following mechanism
seems to be operable.
REACTIVITY OF CHALCONES
The chalcones have been initiated to be useful for the syntheses of multiplicity of
heterocyclic compounds are as under.
1. Chalcones with alkaline hydrogen peroxide in methylene dichloride gives oxirane.30
2. Chalcones with tertiary amine and N-methylmorpholinium salt in acetonitrile by
using o-(diphenyl phosphinyl)hydroxylamine produces aziridines.31
3. Chalcones on reaction with benzamidine hydrochloride under microwave assisted
condition in DMA affords dihydropyrimidines.32
4. Chalcones on reaction with 2-aminopyridine in glacial acetic acid affords
pyridopyrimidines.33
5. Chalcone gives imine derivatives with amine in presence of sulfuric acid as catalyst.34























































7. Chalcones on reaction with thiourea in presence of alkali/acid yields
2- thienopyrimidines.36
8. Chalcones react with P2S5 yielded 2-isothiazolidines.
37
9. Chalcones react with sodium nitrile in presence of glacial acetic acid in ethanol
produces 2-1H-pyrimidines.38
10. Isoxazoles39 can be prepared by the treatment of chalcones with hydroxylamine
hydrochloride and sodium acetate.
11. Chalcones on condensation with 2-aminobenzothiazole in ethanol forms 2,3-
dihydro-1,5-benzothiazepine.40
12. Pyrazoline41 and its derivatives can be prepared by the condensation of
chalcones with hydrazine hydrate and acetic acid.
13. Chalcones on treatment with guanidine hydrochloride in presence of alkali
affords 2-amino pyrimidines.42
14. Cyanopyridone derivatives43 can be prepared by the condensation of
chalcones with ethyl cyanoacetate.
THERAPEUTIC IMPORTANCE
Chalcones are potential biocides, some naturally occurring antibiotics and amino
chalcones probably own their genetic activity due to the presence of á ,â-unsaturated
carbonyl group. Some of them are as below.
1. Antitumor44,45
2. Anticancer46,47













Nakahara Kazuhiko et al.62 have synthesized chalcones as carcinogen inhibitors.
Antitubercular agents of chalcone derivatives have been prepared by Lin Yuh-Meei et
al.63 Ko Horng-Huey et al.64 have reported chalcones as anti-inflammatory agents. Some
of the chalcones have been reported for their use for treatment of glaucoma65 and
antifungal,66 aldose reductase inhibitors,67 anticancer68 activities. Satyanarayana M. et
al.69 have synthesized chalcones (2) derivatives as anti hyperglycemic activity.
Hollosy F. et al.70 have prepared some new chalcones as plant derived protein
tyrosine kinase inhibitors as anticancer agents. Meng C. Q. et al.71 have discovered
some novel heteroaryl substituted chalcones as inhibitors of TNF-alpha-induced VCAM-
1 expression. V. K.Ahluwalia et al.72 have noted that 5-cinnamoylchalcones have exposed
good as antibacterial agents. Woo Duck Seo et al.73 have synthesized chalcone derivatives
(3) reported as α-glucosidase inhibitors.
A. Araico and co-workers74 have synthesized chalcone derivatives as inhibitor
of cyclo-oxygenase-2 and 5-lipoxygenase. Alcaraz M. J. et al.75 have described the
role of nuclear factor-kappa-B and hemeoxygenase-1 in the action of an anti-
inflammatory chalcone derivatives in RAW 264.7 cells. Xue C. X. et al.76 documented
chalcones as antimalarial agents. Prem P. Yadav and co-workers77 have synthesized
nitrogen and sulfur containing furanoflavonoids and thiophenylflavonoids which have been
screened for antifungal and antibacterial activity. Opletalova Veronika et al.78 have
synthesized chalcones and screened for their cardiovascular agents. Ko H. H. et al.79

















S. et al.80 synthesized some novel chalcones as potent tyrosinase inhibitors. Fu Y. et al.81
have demonstrated chalcones as licochalcone-A. Nerya O. et al.82 have prepared some
new chalcones as potent tyrosinase inhibitors. Sung Hee Lee and co-workers83 have
designed and synthesized chalcones and reported their anti-inflammatory activity. Paula
Boeck, Camila Alves and Bartira Rossi-Bergmann84 have synthesized some newer
chalcone analougs (4) which shows antileishmanial activity.
Xiang Wu et al.85 have synthesized ferrrocenyl chalcones and reported their
antiplasmodial activity. Ban H. S. et al.86 have synthesized some newer chalcones as
inhibition of lipopolysaccharide-induced expression of inducible nitric oxide synthase
and tumor necrosis factor-alpha by 2'-hydroxychalcone derivatives in RAW 264.7 cells.
Simon Feldbaek Nielsen et al.87 have described some chalcone derivatives (5) as
antibacterial agents.
Morever, Aneta Modzelewska et al.88 have prepared novel chalcone and bis
chalcone derivatives having anticancer activity. Seo et al.89 reported the chalcones as a
glucosidase inhibitors.
Work done from our laboratory
V. V. Kachhadia synthesized some chalcone derivatives (6) containing



















K. H. Popat has synthesized some chalcone derivatives (7) and use them as a synthon
for the synthesis of cyanopyran and cyanopyridine derivatives91 as biological active
molecules, thiosemicarbazone and oxirane derivatives as potent antitubercular agents92.
Synthesis, selective antitubercular and antimicrobial inhibitory activity of some
chalcone derivatives (8) have been reported by P. T. Chovatia93. D. H. Vyas94 has
reported Synthesis, antitubercular and antimicrobial activities of some new pyrazoline
and isoxazole derivatives. He also reported synthesis and antimicrobial activity of some
new cyanopiperidinones and cyanopyridones95 and synthesis and biological activity of
some pyrazoline derivatives from chalcones (9)96.
D.  J .  Paghdar 97 synthes ized chalcone der ivat ives  (10)  bear ing 4-
(methylsulfonyl)phenyl nucleus and reported as potent antitubercular and antimicrobial
agents Synthesis and evaluation of pharmacological activity of chalcone derivatives (11)
have been reported by M. R. Patel98. Synthesis of some new pyrazolo[3,4-d]pyrimidines
and thiazolo[4,5-d]pyrimidines from arylidine and evaluation of their antimicrobial
activities was reported by J. D. Akbari99.
Morever M. J. Ladani100 reported synthesis and biological study of chalcones
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These suitable scrutiny led us to explore chalcone chemistry by synthesizing several
derivatives like Pyrazolines and Cyclohexenones bearing 3-isopropyl-4-methoxy-
benzaldehyde system for curative value, in order to achieving superior therapeutic agents,
this study described as under.
SECTION-I: SYNTHESIS AND BIOLOGICAL SCREENING OF (E)-3-(3-
ISOPROPYL-4-METHOXYPHENYL)-1-ARYL-PROP-2-EN-1-
ONES.
SECTION-II: SYNTHESIS AND BIOLOGICAL SCREENING OF 1-ACETYL-
  3-ARYL-5-(3-ISOPROPYL-4-METHOXYPHENYL)PYRAZOLES.


























SYNTHESIS AND BIOLOGICAL SCREENING OF (E)-3-(3-ISOPROPYL-4-
METHOXYPHENYL)-1-ARYL-PROP-2-EN-1-ONES
With the biodynamic activities of chalcones and as a fine synthon for different
heterocyclic rings, the awareness has been paying attention on the creation of new
chalcones. With a observation to obtained compounds having better therapeutic activity,
we have synthesized (E)-3-(3-isopropyl-4-methoxyphenyl)-1-aryl-prop-2-en-1-ones by
the condensation of 3-Isopropyl-4-methoxybenzaldehyde with various aromatic ketones
by using alkali as catalyst.
The constitution of the synthesized compounds have been characterized by using
elemental analysis, Infrared, 1H NMR spectroscopy and further supported by mass
spectroscopy.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards A. niger at a concentration of 40 μg/ml. The biological activities

















Melting points of all the synthesized compounds were taken in open capillary
bath on controlled temperature heating mental. The crystallization of all the compounds
was carried out in appropriate solvents. TLC was carried out on silica gel-G as stationary
phase. 40 % Ethyl acetate in Hexane was used as a mobile phase.
[A] General procedure for the preparation of (E)-3-(3-Isopropyl-4-methoxy-
phenyl)-1-aryl-prop-2-en-1-ones.
A solution of substituted acetophenone (0.01 mole) in minimum quantity of ethanol
(10 ml) was added to a 3-isopropyl-4-methoxybenzaldehyde (1.78 gm, 0.01 mole) in
ethanol (10 ml). To this mixture 40 % NaOH (1 ml) as catalyst was added to make it
alkaline. The reaction mixture was then stirred for 24 hr. at room temperature. The
product was isolated by filtration and crystallized from suitable solvent. The physical
constants of the product are recorded in Table-4a.
[B] Biological screening of (E)-3-(3-Isopropyl-4-methoxyphenyl)-1-aryl-
prop-2-en-1-ones.
Antimicrobial testing was carried out as described in Part-A, Part-1, Section-I,





Table-4a: Physical constants of (E)-3-(3-Isopropyl-4-methoxyphenyl)-1-aryl-prop-
2-en-1-ones.
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SPECTRAL STUDY 
































































































Instrument: Shimadzu FTIR-8400 using KBr DRS techniques. The percentage transmittance is 
given in cm-1 and frequency range is between 400-4000cm-1. 
Type Vibration Mode Frequency cm-1
Alkane -CH3
C-H str. (asym.) 2976
C-H str. (sym.) 2869
C-H i.p.d (asym) 1419




C-H  i.p. bending 1114
C-H o.p bending 841
Chalcone -C=O str. 1657
Vinyl -CH=CH- str. 819
-C-O-C- 1029
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of Protons Multiplicity Inference
J value
in Hz
1 1.24-1.26 6H doublet Ar-CH(CH3)2 7.0
2 3.29-3.36 1H multiplet Ar-CH(CH3)2 -
3 3.91 3H singlet Ar-OCH3 -
4 6.88-6.90 1H doublet Ar-Hf 8.3
5 7.32-7.35 1H doublet -Hd 15.6
6 7.48-7.51 2H multiplet Ar-He + Ar-Hg -
7 7.79-7.83 1H doublet -Hc 15.6
8 8.11-8.14 2H dd Ar-Hb,b' 9.1 & 2.1
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The chemistry of pyrazoles has been reviewed by Jarobe in 1967. Pyrazoles
have attracted attention of medicinal chemists for both with regard to heterocyclic
chemistry and the pharmacological activities associated with them. Pyrazole have been
studied extensively because of ready accessibility, diverse chemical reactivity, broad
spectrum of biological activity1 and varieties of industrial applications2.
Pyrazole has three possible tautomeric structures. But 2-pyrazole 1 consist a
unique class of nitrogen containing five member heterocycles.
As evident from the literature in recent years a significant portion of research
work in heterocyclic chemistry has been devoted to pyrazoles containing different alkyl,
aryl and heteroaryl groups as substituents.
SYNTHETIC ASPECT
Different methods are available from the literature for the preparation of 2-
pyrazole derivatives. The most common procedure for the synthesis of 2-pyrazoles is
the reaction of an aliphatic or aromatic hydrazine with α,β-unsaturated carbonyl
compounds.
ALTERNATIVE SYNTHETIC ROUTES FOR IMPROVED YIELD, SHORTER



















L. L. De3 reported cellulose beads as a new versatile solid support for microwave-
assisted synthesis of pyrazole and isoxazole libraries.
Wang resin supported solid - phase synthesis of pyrazoledicarboxylic acid
derivatives by functionalization of cyanoformate was reported by C. F. Morelli et al.4
Similarly many other solid phase synthesis of pyrazole moiety were reported using
different solid support such as (4-formyl-3-methyoxyphenoxy)methylpolystyrene (FMP)
resin5, polymer-supported vinylsulfone6, Kenner ‘safety catch’ resin7, KOH powder8.
Liquid-Phase Synthesis
X. L. Ren and coworkers9 have synthesized pyrazole derivatives using liquid
phase synthesis strategy.
V. N. Pathak and group reported 3,5-diarylpyrazole synthesis using phase transfer















































Microwave irradiation and solvent-free conditions was reported for the rapid
and efficient synthesis by M. A. H. Zahran13.
New Green approaches to the synthesis of pyrazole derivatives were reported
by A. Corradi et al.14
Similarly in literature there are number of the reports that uses the microwave
irradiation for the rapid synthesis, high yield or towards the green approach of the reaction
under solvent free conditions some of them are reported as below.
 S. S. Chauhan derives pyrazoles from diaryl 1,3-diketones15, it also prepared
by 1,3-dipolar cycloaddition of diazo compounds to acetylene derivatives16, by
regiospecific  synthesis  of 5-trifluoromethyl-4,5-dihydropyrazoles17, by microwave-
mediated combinatorial  synthesis18, by dry media19, by regiospecific synthesis20, by p-
toluenesulphonic acid21, Microwave synthesis22.
P. D. Sauzem23 reported design and microwave-assisted synthesis  of 5-
trifluoromethyl-4,5-dihydro-1H-pyrazoles and one step synthesis of 3,5-disubstituted
pyrazoles were  carried out by M. Outirite24.
Catalysts
Many of the organic chemists prefer to use catalyst to get the desire product with
high yield and within sort reaction time and to convert the reaction condition from drastic
to easily operational with some specific catalyst.
R. Ali reported stereoselective synthesis of N-vinyl pyrazoles in solvent-free
conditions using dipotassium hydrogen phosphate powder25, zinc-catalyzed synthesis of




























In literature there are numbers of the catalysts are used for the synthesis of pyrazole
system like Conjugate base27, Iodine(III)28, Hafnium chloride29, Tungstophosphoric acid30,
p-toluenesulphonic acid31, Sulfamic acid32, Ytterbium(III)perfluorooctanoate33, Silver(I)34
and organocatalysts35.
REACTION MECHANISM
The following mechanism seems to be operable for pyrazoline by the condensation
of chalcones with hydrazine hydrate.36
Nucleophillic attack by hydrazine at the β-carbon of the α,β-unsaturated carbonyl
system I forms species II, in which the negative charge is mainly accommodated by the
electronegative oxygen atom.
Proton transfer from the nitrogen to oxygen produces an intermediate and which
simultaneously ketonises to ketoamine III. Another intramolecular nucleophillic attack
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transfer from nitrogen to oxygen leads ultimately to hydroxyl amine IV. The later with a
hydroxy group and amine group on the same carbon loses water easily to yield the
pyrazolines V.
THERAPEUTIC IMPORTANCE
From the literature survey, it was revealed that 2-pyrazolines are better therapeutic













M. K. Shivnanda and co-workers53 have prepared pyrazolines and reported their
antibacterial activity. Antimycotic activity of pyrazoline derivatives 2 have been reported
by Joanna Matysiak and Andrzej Niewiadomy54. J. Almstead et al.55 have prepared
pyrazolines as vascularization agent. T. Z. Gulhan and coworkers56 have prepared










S. Sharma et al.57 have synthesized pyrazolines and tested their anti-inflammatory
activity. Antiamoebic activity of pyrazoline derivatives have been reported by Asha
Budakoti and co-workers58. J. H. Ahn et al.59 have reported as inhibition of cyano-
pyrazoline (3) derivatives as potent antidiabetic agents. T. S. Jeong et al.60 have
synthesized some novel 3,5-diaryl pyrazolines (4) as human acyl-Co A: cholesterol
acyltransferase inhibitors. G. Ucar et al.61 reported pyrazolines as cholinstearase and
selective monoamine oxidase-B inhibitiors for the treatment of parkinson and alzheimer’s
diseases. M. N. Nasr et al.62 have reported the synthesis of newer arylthiazolylpyrazoline
derivatives as anti-inflammatory agents. M. A. Berghot et al.63 have prepared for convergent
synthesis and antibacterial activity of pyrazole and pyrazoline derivatives of diazepam.
N. Gokhan et al.64 have synthesized the pyrazoline derivatives of 1-N-substituted
thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines (5) as MAO inhibitors. Mohammad Abid
and Amir Azam65 have synthesized 1-N-substituted cyclized pyrazoline of
thiosemicarbazones (6) and reported as antiamoebic agents. V. Malhotra et al.66 have
documented new pyrazolines as a cardiovascular agents. Antidepressant activity of
pyrazoline derivatives have been reported by Y. R. Prasad and co-worker67.
Abd El-Galil E. Amr et al.68 have synthesized some new 3-substituted
androstano[17,16-c]-5,2-aryl-pyrazolines and reported their antiandrogenic activity. B.
Bizzarri et al.69 have reported in vitro selective anti-helicobacter pylori activity (7) of

























pyrazoline derivatives. Bhat and co-workers70 reported cytotoxic properties of pyrazoline
derivatives. Antibacterial activity of pyrazoline derivatives have been reported by A. M.
Gandhi and co-workers71. B. Shivarama Holla et al.72 have synthesized pyrazolines as
antibacterial agents. S. P. Hiremath et al.73 have synthesized pyrazolines as analgesic,
anti-inflammatory and antimicrobial agents. Rajendra Prasad et al.74 have synthesized
some 1,3,5-triphenyl-2-pyrazolines (8) and 3-(2"-hydroxynaphthalen-1"-yl)-1,5-
diphenyl-2-pyrazolines and reported as antidepressant agents. J. H. M. Lange et al.75
synthesized and reported 3,4-diaryl pyrazoline analogues as potent and selective CB1
cannabinoid receptor antagonists. N. T. Ha- Duong et al.76 have been synthesized some
pyrazole derivatives as inhibitors for the active sites of human liver cytochromes P450
of the 2C subfamily.
X. Zhang and co-workers77 have been prepared pyrazoline derivatives (9) as
potent selective androgen receptor modulators. M. E. Camacho and co-workers78 have
been reported 4,5-dihydro pyrazoles (10) as Inhibitory nNOS activity in rat brain.
F. Chimenti and co-workers79 have been demonstrated a novel series of 1-acetyl-
3-(4-hydroxy-and 2,4-dihydroxyphenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole
derivatives (11) and investigated for the ability to selectively inhibit the activity of
monoamine oxidase (MAO). Y. R. Huang et al.80 have been prepared a series of 4-
alkyl-1,3,5-triarylpyrazoles (12) as ligands for the estrogen receptor. C. D. Cox et al.81
and J. R. Goodell et al.82 have been reported separately some pyrazoline derivatives as
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parkinson’s disease. A series of 3-(4-fluorophenyl)-4,5-dihydro-N-[4-(trifluoromethyl)-
phenyl]-4-[5-(trifluoromethyl)-2-pyridyl]-1H-pyrazole-1-carboxamide has been
synthesized and studied for their potent foliar activity against both lepidoptera and
orthoptera insects by P. K. Leonard et al.83 Bruce G. Szczepankiewicz et al.84 have been
prepared some pyrazole derivatives as antimitotic agents with activity in multi-drug
resistant cell lines.
Guniz Kuchkguzel et al.85 have synthesized pyrazolines as a antimicrobial and
anticonvulsant agents. Gulhan T. Z. and co-workers86 have prepared pyrazolines as a
hypotensive agent.
Work done from our laboratory
Synthesis anticancer, antitubercular and antimicrobial activity of 1-substituted 3-
aryl-5-(3’-bromophenyl)-pyrazoleines (13) have been reported by K. S. Nimavat87. D.
H. Vyas88 reported synthesis and biological activity of some pyrazoline derivatives (14)
bearing 3,5-dibromo-4-methoxybenzaldehyde nucleus.
Synthesis, selective antitubercular and antimicrobial inhibitory activity of 1-acetyl-
3,5-diphenyl-4,5-dihydro-(1H)-pyrazole derivatives (15) have been reported by P. T.
Chovatia89. T. K. Dave90 reported synthesis, antitubercular and antimicrobial evaluation
of pyrazole derivatives bearing nicotinic acid nucleus.
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Synthesis of some pyrazolo[3,4-d]pyrimidines and thiazolo[4,5-d]pyrimidines
and evaluation of their antimicrobial activities with derivatives of urea91 and thiourea
(16)92 was reported by J. D. Akbari.
Literature survey reveals that the compounds bearing pyrazole moiety possess
potential drug activity. Looking to the diversified biological activities we have synthesized
some pyrazole derivatives in order to achieving better therapeutic agents. These studies
are described in following section.
























SYNTHESIS AND BIOLOGICAL SCREENING OF 1-ACETYL-3-ARYL-5-(3-
ISOPROPYL-4-METHOXYPHENYL)PYRAZOLES.
Pyrazole derivatives represent one of the most active class of compounds having
a wide spectrum of biological activities. Looking to the interesting properties of pyrazoles
it was considered worthwhile to synthesize a series of pyrazoles for obtaining biologically
potent agents which were prepared by reacting chalcones with hydrazine hydrate in
glacial acetic acid.
The constitution of the synthesized compounds have been characterized by using
elemental analysis, Infrared, 1H NMR spectroscopy and further supported by mass
spectroscopy.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards A. niger at a concentration of 40 μg/ml. The biological activities

















Melting points of all the synthesized compounds were taken in open capillary
bath on controlled temperature heating mental. The crystallization of all the compounds
was carried out in appropriate solvents. TLC was carried out on silicagel-G as stationary
phase. 30 % Ethyl acetate in Hexane was used as a mobile phase.
[A] Preparation of (E)-3-(3-Isopropyl-4-methoxyphenyl)-1-aryl-prop-2-en-1-
ones.
See Part-B, Section-I, Experimental section [A].
[B] General procedure for the preparation of 1-Acetyl-3-aryl-5-(3-isopropyl-
4-methoxyphenyl)pyrazoles.
A mixture of (E)-3-(3-isopropyl-4-methoxyphenyl)-1-aryl-prop-2-en-1-ones
(0.01 mole) and hydrazine hydrate (0.04 mole) in acetic acid (20 ml) was refluxed on an
oil-bath for 10-11 hrs. The resulting solution was poured on crushed ice. The solid
product was isolated and crystallized from suitable solvent. The physical constants of
the product are recorded in Table-5a.
[C] Biological screening of 1-Acetyl-3-aryl-5-(3-isopropyl-4-methoxyphenyl)-
pyrazoles.
Antimicrobial testing was carried out as described in Part-A, Part-1, Section-I,
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SPECTRAL STUDY 


















































































Instrument: Shimadzu FTIR-8400 using KBr DRS techniques. The percentage transmittance is 
given in cm-1 and frequency range is between 400-4000cm-1. 
Type Vibration Mode Frequency cm-1
Alkane -CH3
C-H str. (asym.) 2957
C-H str. (sym.) 2833
C-H i.p.d (asym) 1428




C-H  i.p. bending 1109

















1H NMR spectra of 1-Acetyl-3-(4-nitrophenyl)-5-(3-isopropyl-4-methoxyphenyl)
-pyrazole.


























of Protons Multiplicity Inference
J value in
Hz
1 1.17-1.19 6H doublet Ar-CH(CH3)2 7.0
2 2.43 3H singlet -CO-CH3 -
3 3.15-3.21 1H dd -CH2- 4.76 & 17.7
4 3.22-3.39 1H multiplet Ar-CH(CH3)2 -
5 3.70-3.76 1H dd -CH2- 5.76 & 17.7
6 3.78 3H singlet Ar-OCH3 -
7 5.59-5.63 1H dd -Hc 4.76 & 11.9
8 6.76-6.78 1H doublet Ar-He 8.4
9 6.96-6.98 1H dd Ar-Hd 2.3 & 8.4
10 7.05-7.06 1H doublet Ar-He 2.3
11 7.88-7.90 2H dd Ar-Hb,b' 8.1 & 7.2
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Cyclohexenones are derivatives of cyclohexane with carbonyl group at position-
1 and double bond at position-2. There are different types of cyclohexenone derivatives
but the greatest difference in structure and properties is exerted by the groups attached
to carbon atom.
Cyclohexenones is the parent of a series of compounds that is important in
agricultural and medicinal chemistry. Cyclohexenones can be conveniently synthesized
by the treatment of á ,â-unsaturated carbonyl compounds with ethyl acetoacetate in basic
media.
In recent years cyclohexenone derivatives have gained lot of interest because of
their prominent pharmaceutical properties.
SYNTHETIC ASPECT
Different methods for the preparation of cyclohexenone derivatives have been
described in literature.1-9
1. A review of the earlier literature by Gerald et al.10 described representative
synthetic procedure of cyclohexenone derivatives.
2. Byong-Don Chong et al.11 have been prepared cyclohexenone derivatives by
tandem michael addition-aldol condensation of â-keto esters to conjugate enones















3. Andrea Buzas et al.12 have been prepared cyclohexenone by reaction of various
substituted 5-en-2-yn-1-yl acetates with using biphenyl phosphine as catalyst in
methanol in basic media.
4. Ken Tanaka et al.13 have synthesized cyclohexenone from 4-alkynals and alkynes
in presence of Rh catalyst via novel [4+2] annulation.
5. H. Surya Prakash Rao and co workers14 reported solvent-free microwave-



























































The addition reaction between ethyl acetoacetate and á,â-unsaturated ketones
give cyclohexenone via Michael addition. This reaction has been carried out in basic
media by using sodium ethoxide or anhydrous K2CO3 in acetone. During the reaction
nucleophillic addition of carbanion takes place to the C=C of the acceptor. The á,â-
unsaturated compound is known as acceptor and ethyl acetoacetate is known as donor.
THERAPEUTIC IMPORTANCE
Cyclohexenone and its derivatives are widely used in pharmaceutical industry.
Considerable interest has been shown in the chemistry of cyclohexenone due to their






















































Antimicrobial activities of cyclohexenones have been studied by Salama and Al-
shikh.26 Cyclohexenone possess neutropeptide α-receptor antagonist activity which was
reported by Takehiro and co-workers.27 Broughton Howard et al.28 have demonstrated
cyclohexenones as GABA a5 receptor ligands for enhancing coagulating properties.
Cyclohexenones possess inhibitory activity against the growth of lettuce seeding found
by Kimura and co-workers.29 Alekseeva L. M. and co-workers30 have synthesized
cyclohexenone derivatives which are useful as neurotropic activity. Patricia Silva Melo
et al.31 have been equipped cyclohexenone (1) as gastroprotective effect.
Erin Joseph et al.32 have been synthesized 2-crotonyloxymethyl-2-cyclohexenones
2 and reported as antitumer agents. N. D. Eddington et al.33 have prepared potential
enaminone as anticonvulsants. Chuihua Kong et al.34 have reported some cyclohexenone
derivatives as their inhibitory activity on weeds and fungal pathogens. T. Sunazuka and
co-workers35 reported cyclohexenone derivatives as potent, orally bioactive and selective
inhibitors of acetylcholinesterase. Alan J. Anderson et al.36 have synthesized
cyclohexenone derivatives and studied on the anticonvulsant activity and potential type-
























Edward J. et al.37 have synthesized 2,3-dihydro-5-(3-oxo-2-cyclohexen-1-yl)-
2- benzofurancarboxylic acids and their salts which are used in the treatment of brain
injury. K. R. Scott et al.38 have documented cyclohexenone derivatives (4) and studied
on the anticonvulsant activity. Toshiyuki et al.39 have prepared some novel cyclohexenone
and screened for their allergy inhibitor, antithrombotic platelet aggregation inhibitors
and fibrinogen antagonist activity. Cyclohexenone and its derivatives have been prepared
and reported as broad spectrum of physiological properties viz bactericidal40 etc.
Y. F. Shealy et al.41 have demonstrated cyclohexenones as anticancer agents.
Mathias Alterman et al.42 have designed and fast synthesis of C-terminal duplicated potent
C2-symmetric P1/P1’-modified HIV-1 protease inhibitors. F. Nara et al.43 synthesized
some cyclohexenones as powerful and specific inhibitor of neutral sphingomyelinase
(NSMase). T. Kolter et al.44 have anticipated cyclohexenone derivatives to be a promising
agent for the treatment of ceramide-mediated pathogenic states such as inflammation
and immunological and neurological disorders. Q. Zhang and co-workers45 have prepared
glutathionylated 2-exomethylenecyclohexenone (5) as antitumer agents. The presence
of pesticidal activity among cyclohexenone derivatives is well documented.
The compound 2-{(E,Z)-1-[(2R,S)-2-(4-chlorophenoxy)propoxyimino]butyl}-
3-hydroxy-5-thian-3-yl)cyclohex-2-en)-one (6) has been marketed under the name of

















Work done from our laboratory
Synthesis and pharmacological evaluation of 6-carbethoxy-5-(3'-bromophenyl)-
3-aryl-2-cyclohexenones (7)  and 6-aryl-4-(3'-bromophenyl)-3-oxo-2,3a,4,5-
tetrahydro-2H-indazoles was reported by K. S. Nimavat46.
K. H. Popat47 have been reported synthesis, anticancer, antitubercular and
antimicrobial activity of 6-carbethoxy-5-(3'-chlorophenyl)-3-aryl-2-cyclohexenones (8)
and 6-aryl-4-(3'-chlorophenyl)-3-oxo-2,3a,4,5-tetrahydro-1H-indazoles. V. V.
Kachhadia48 reported synthesis, antitubercular and antimicrobial activity of 6-carbethoxy-
5-aryl-3-[p-(3'-chloro-2'-benzo[b]thiophenoyl amino)phenyl]-2-cyclohexenones (9).
Looking to the biological profile of cyclohexenone derivatives, we have































   SECTION-III
SYNTHESIS AND BIOLOGICAL SCREENING OF ETHYL 4-ARYL-6-(3-
ISOPROPYL-4-METHOXYPHENYL)-2-OXO-CYCLOHEX-3-ENE-1-
CARBOXYLATES.
Cyclohexenone derivatives have considerable attention in view of their potential
pharmacological properties such as antimicrobial, anticonvulsant anticancer, etc. Led
by these considerations, the preparation of cyclohexenone derivatives have been
undertaken. The synthesis was carried out by the condensation of (E)-3-(3-isopropyl-
4-methoxyphenyl)-1-aryl-prop-2-en-1-ones with ethylacetoacetate in presence of basic
catalyst like K2CO3 shown as under.
The constitution of the synthesized compounds have been characterized by using
Elemental analysis, Infrared, 1H Nuclear Magnetic Resonance spectroscopy and further
supported by mass spectroscopy.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards A. niger at a concentration of 40 μg/ml. The biological activities

























Melting points of all the synthesized compounds were taken in open capillary
bath on controlled temperature heating mental. The crystallization of all the compounds
was carried out in appropriate solvents. TLC was carried out on silicagel-G as stationary
phase. 20 % Ethyl acetate in Hexane was used as a mobile phase.
[A] Preparation of (E)-3-(3-Isopropyl-4-methoxyphenyl)-1-aryl-prop-2-en-1-
ones.
See Part-B, Section-I, Experimental section [A].
[B] General procedure for the preparation of Ethyl 4-aryl-6-(3-isopropyl-4-
methoxyphenyl)-2-oxo-cyclohex-3-ene-1-carboxylates.
A mixture of (E)-3-(3-isopropyl-4-methoxyphenyl)-1-aryl-prop-2-en-1-one
(0.01 mole), ethylacetoacetate (1.14 gm, 0.01 mole) and K2CO3 (1.38 gm, 0.01 mole)
was taken into dry acetone (25 ml) and the mixture was stirred at room temperature till
the acetone is evaporated off. The contents were neutralized with HCl and poured onto
crushed ice. The product separated was filtered and crystallized from suitable solvent to
give analytically pure product. The physical constants of the product are recorded in
Table-6a.
[C] Biological screening of Ethyl 4-aryl-6-(3-isopropyl-4-methoxyphenyl)-2-
oxo-cyclohex-3-ene-1-carboxylates.
Antimicrobial testing was carried out as described in Part-A, Part-1, Section-I,
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SPECTRAL STUDY 
IR spectra of Ethyl 4-(4-nitrophenyl)-6-(3-isopropyl-4-methoxyphenyl)-2-oxo-
















































































































Instrument: Shimadzu FTIR-8400 using KBr DRS techniques. The percentage transmittance is 
given in cm-1 and frequency range is between 400-4000cm-1. 
Type Vibration Mode Frequency cm-1
Alkane -CH3
C-H str. (asym.) 2971
C-H str. (sym.) 2835
C-H i.p.d (asym) 1459




C-H  i.p. bending 1188
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of Protons Multiplicity Inference J value in Hz
1 1.05-1.10 3H triplet -CH2-CH3 7.88
2 1.16-1.19 6H doublet -CH(CH3)2 3.52
3 2.11-2.16 1H triplet -CH2- 13.96 & 2.96
4 2.36-2.42 1H triplet -CH2- 12.92 & 11.76
5 2.68-2.71 1H triplet -He 12.76 & 1.04
6 3.12-3.15 1H doublet -Hd 13.8
7 3.24-3.28 1H multiplet -CH(CH3)2 -
8 3.78 3H singlet Ar-OCH3 -
9 4.01-4.05 2H multiplet -CH2-CH3 -
10 5.89 1H singlet -Hc -
11 6.77-6.79 1H doublet Ar-Hg 8.64
12 7.10-7.12 2H doublet Ar-Hf+Ar-Hh 7.28
13 7.75-7.77 2H doublet Ar-Ha,a' 8.76
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Pyrimidine is the most important member of all the diazines as this ring system
occurs widely in living organisms. Purine, uric acid, barbituric acid, anti-malarial and
anti-bacterial agents also contain the pyrimidine ring. The chemistry of pyrimidine has
been widely studied. Pyrimidine was first isolated by Gabriel and Colman in 1899. Since
pyrimidine is symmetrical about the line passing C-2 and C-5, the positions C-4 and C-
6 are equivalent and so N-1 and N-3 are equivalent. When a hydroxyl or amino group is
present at the 2-, 4- or 6- position than they are tautomeric with oxo and imino
respectively.
Although the importance of dihydroazines (particularly those containing the 1,4-
dihydropyrimidine and dihydropyridine motif1) for clarifying a wide range of theoretical,
medicinal and biological problems, the chemistry of this group of compounds is still
extremely spotty2-6. From the theoretical point of view, it is essential to predict the
structure, binding properties, chemical reactivity, etc. of dihydro compounds from the
number and positioning of nitrogen atoms in the ring, as well as from the disposition of
double bonds. Such quantum mechanical calculations also enable an evaluation of the
degree of aromatic character in potential homoaromatic and antiaromatic isomers.
Availability of novel model compounds for verifying these predictions would open up
new horizons in theoretical heterocyclic chemistry, particularly in clarifying the structures
leading to spontaneous isomerization of a derivative or in verifying its redox properties.
From the biochemical point of view, dihydroazines are of intense interest because
of presence of this group at the active site of the hydrogen transferring coenzyme
(nicotinamide adenine dinucleotied hdrogenase-NADH or reduced nicotinamide adenine
dinucleotide). This nucleotide, a central participant in metabolic processes in living
organisms, participates in the reduction of various unsaturated functionalities.
In the area of drug development, dihydroazines show great promise, particularly
since the 4-aryldihydropyridines exhibit powerful vasodilation activity via modifying the
calcium ion membrane channel7-10. Additionally, dihydropyridines have been found to
actively transport medication across biological membranes11.
Until recently, most of the information available on dihydroazines centered around
dihydropyridines, with very little data extending to the related dihydropyrimidines.
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This lacuna has motivated our deep involvement in developing dihydropyrimidine
chemistry12, These molecules have long been considered unstable for oxidation,
polymerization or disproportionation reactions13.
Figure below present in the drawing five possible isomeric structures of
dihydropyrimidines, exhibiting different positions of the double bonds.
However, these structures are not easy to synthesize and, as a result, most of the
known dihydropyrimidines have either 1,2- or the tautomeric 1,4- and 1,6- geometry. On
the basis of data available in the literature14,15, the dihydropyrimidines can be conveniently
divided into two groups, within each of which interconversion between isomers is possible
under thermal conditions, namely, the 1,4-, 1,6-, and 4,5- compounds, and the 1,2- and
2,5- isomers. It is worthwhile to note that, while thermal interconversion between the two
groups is not observed, photochemical rearrangement of 1,4- (or 1,6-) dihydropyrimidines
to 1,2-isomers has been reported16,17.
It should be stressed that dihydroazines take part in various isomerization
processes, usually characterized by reversible or irreversible migrations within the ring,
the study of which is still in its infancy. Hydrogen migration, for example, is classified
either as rearrangement or tautomerism depending on its kinetic and thermodynamic
parameters, the former term is reserved for irreversible processes, while the latter is
used to describe fast reversible exchanges18.  A study of isomerization in
dihydropyrimidines provides an excellent opportunity for clarifying the factors regulating
these processes.
After successfully developing versatile synthetic techniques for obtaining a variety
of 1,4- and 1,6-dihydropyrimidines19-21, as well as the observation of amidinic
tautomerism between the two22,23, A. L. Weis et al.14 examined the possibility of
preparative synthesis of similarly 1,2-dihydro derivatives and studied their properties.
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allowed hydrogen shift23, of homoaromaticity24,25 or of imine-enamine tautomerism26 in
these compounds, behaviors of which have been seen in other systems.
To date few reports on the formation of 1,2-dihydropyrimidines exist in the
literature, and in those cases where a product could be isolated and characterized, the
material was either an N-substituted derivative or else it contained geminal disubstitution
at position 2, situations that prevent the molecule from oxidizing to the corresponding
pyrimidine.
Pyrimidine ring carrying various substituents may be built up from two or three
small fragments by the principle synthesis or by a variety of other synthesis, which are
complimentary rather than alternative to it. A second type of synthesis is the isomerisation




In 1893, Italian chemist Pietro Biginelli reported an acid catalyzed
cyclocondensation reaction of ethyl acetoacetate, benzaldehyde and urea. The reaction
was carried out by simply heating a mixture of the three components dissolved in ethanol
with a catalytic amount of HCl at reflux temperature. The product of this novel one-pot,
three-component synthesis that precipitated on cooling of the reaction mixture was

















Alternative synthetic routes for better yield, shorter reaction time to synthesize
new analogs:
Various modifications have been applied to Biginelli reaction to get better yield
and to synthesize biologically active analogs. Different catalysts have been reported to
increase the yield of the reaction. Microwave synthesis strategies have also applied to
shorten the reaction time. Solid phase synthesis and combinatorial chemistry has made
possible to generate library of DHPM analogs.
Catalysts
Min Yang and coworkers28 have synthesized the different DHPMs by using
different inorganic salts as a catalyst. They found that the yields of the one-pot Biginelli
reaction can be increased from 20-50 % to 81-99 %, while the reaction time shorted for
18-24 hr to 20-30 min. This report discloses a new and simple modification of the
Biginelli type reaction by using Yb(OTf)3 and YbCl3 as a catalyst under solvent free
conditions. One additional important feature of this protocol is the catalyst can be easily
recovered and reused.
Indium(III)chloride was emerged as a powerful Lewis catalyst imparting high
region and chemo selectivity in various chemical transformations. B. C. Ranu and
coworkers29 reported indium(III)chloride (InCl3) as an efficient catalyst for synthesis of
3,4-dihydropyrimidn-2(1H)-ones. A variety of substituted aromatic, aliphatic and
heterocyclic aldehydes have been subjected to this condensation very efficiently. Thiourea








































Majid M. Heravi et al. have reported a simple, efficient and cost-effective method
for the synthesis of 3,4-dihydropyrimidin-2(1H)-ones/thiones by one pot three-
component cyclocondensation reaction of a 1,3-dicarbonyl compound, an aldehyde and
urea or thiourea using 12-tungstophosphoric acid30 and 12-molybdophosphoric acid31
as a recyclable catalyst.
A novel covalently anchored sulfonic acid onto the surface of silica was prepared
and investigated for the Biginelli reaction by Satya Paul and co-workers32. The catalyst
is highly stable, completely heterogeneous and recyclable for several times. The workup


















12 - tungstophosphoric acid/























i. 30 % H2O2
















Where X = O or S
Catalyst 1
Stirring, 80°C, 7 - 12 h
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An efficient three-component synthesis of 3,4-dihydropyrimidinones using
trichloroisocyanuric acid (TCCA) as mild, homogeneous and neutral catalyst for Biginelli
reaction in ethanol or DMF under reflux condition33.
Many researchers34-40 have investigated an efficient Biginelli reaction under solvent-
free conditions for one-pot synthesis of 3,4-dihydropyrimidi-2-(1H)ones/thiones using
various catalyst as described under.
Solid phase synthesis
The generation of combinatorial libraries of heterocyclic compounds by solid
phase synthesis is of great interest for accelerating lead discovery and lead optimization
in pharmaceutical research41,42. Multi-component reactions (MCRs) leading to
heterocycles are particularly useful for the creation of diverse chemical libraries, since
the combination of any 3 small molecular weight building blocks in a single operation
leads to high combinatorial efficiancy41-43. Therefore, solid phase modifications of MCRs
are rapidly become the cornerstone of combinatorial synthesis of small-molecule
libraries41-47.
The first solid-phase modification of the Biginelli condensation was reported by
Wipf and Cunningham48 in 1995. In this sequence, γ-aminobutyric acid derived urea
was attached to Wang resin using standard procedures. The resulting polymer-bound
urea was condensed with excess â-ketoester and aromatic aldehydes in THF at 55 °C
in the presence of a catalytic amount of HCl to afford the corresponding immobilized
DHPMs. Subsequent cleavage of product from the resin by 50 % trifluoroacetic acid



















Weiwei Li and Yulin Lam49 described the synthesis of 3,4-dihydropyrimidin-2-
(1H)ones/thiones using sodium benzenesulfinate as a traceless linker. The key steps
involved in the solid-phase synthetic procedure include sulfinate acidification,
condensation of urea or thiourea with aldehydes and sulfinic acid and traceless product
release by a one-pot cyclization-dehydration process. Since a variety of reagents can
be used, the overall strategy appears to be applicable to library generation.
Gross et al.50 developed a protocol for based on immobilized á -ketoamides to
increase the diversity of DHPM. The resulting synthetic protocol proved to be suitable
for the preparation of a small library using different building blocks. They found that the
expected DHPM derivatives were formed in high purity and yield, if aromatic aldehyde
and á-ketoamide building blocks were used. The usage of an aliphatic aldehyde leads to




































































In the solid phase synthesis there are some disadvantages of this methodology
compared to standard solution-phase synthesis, such as difficulties to monitor reaction
progress, the large excess of reagents typically used in solid-phase supported synthesis,
low loading capacity and limited solubility during the reaction progress and the
heterogeneous reaction condition with solid phase51. Recently, organic synthesis of small
molecular compounds on soluble polymers, i.e. liquid phase chemistry has increasingly
become attractive field52. It couples the advantages of homogeneous solution chemistry
with those of solid phase chemistry.
Moreover owing to the homogeneity of liquid-phase reactions, the reaction
conditions can be readily shifted from solution-phase systems without large changes and
the amount of excessive reagents is less than that in solid-phase reactions. In the recent
years, Task Specific room temperature Ionic Liquids (TSILs) has emerged as a powerful
alternative to conventional molecular organic solvents or catalysts. Liu Zuliang et al.53
reported cheap and reusable TSILs for the synthesis of 3,4-dihydropyrimidin-2(1H)-
ones via one-pot three component Biginelli reaction.
Ionic liquid-phase bound acetoacetate react with thiourea and various aldehydes
with a cheap catalyst to afford ionic liquid-phase supported 3,4-dihydropyrimidin-2(1H)-
thiones by Jean Pierre Bazureau and co-workers54. 3,4-Dihydropyrimidinones was
synthesized in one-pot of aldehydes, â-dicarbonyl compounds and urea, catalyzed by

































In general, the standard procedure for the Biginelli condensation involves one
pot condensation of the three building blocks in a solvent such as ethanol using a strongly
acidic catalyst that is hydrochloric acid56. One major drawback of this procedure, apart
from the long reaction times involving reflux temperatures, are the moderate yields
frequently observed when using more complex building blocks. Microwave irradiation
(MWI) has become recognized tool in organic synthesis, because the rate enhancement,
higher yields and often, improved selectivity with respect to conventional reaction
conditions57. The publication by Anshu Dandia et al.58 described microwave-enhanced
solution-phase Biginelli reactions employing ethyl acetoacetate, thiourea and a wide
variety of aromatic aldehydes as building blocks. Upon irradiation of the individual
reaction mixtures (ethanol, catalytic HCl) in an open glass beaker inside the cavity of a
domestic microwave oven the reaction times were reduced from 2 – 24 hours of
conventional heating 80 °C, reflux to 3 – 11 minutes under microwave activation (ca.
200 – 300 W). At the same time the yields of DHPMs obtained were markedly improved
compared to those reported earlier using conventional conditions.
In recent years, solvent free reactions using either organic or inorganic solid
supports have received increasing attention59. There are several advantages to performing
















































advantages due to the absence of solvent. In addition, solvent free MWI processes are
also clean and efficient. M. Gopalakrishnan and co-workers have reported Biginelli
reaction under microwave irradiation in solvent-free conditions using activated fly ash
as a catalyst, activated fly ash, an industrial waste (pollutant) is an efficient and novel
catalyst for some selected organic reactions in solvent free conditions under microwave
irradiation60.
Ultrasound assisted synthesis
Ultrasound as a green synthetic approach has gradually been used in organic
synthesis over the last three decades. Compared with the traditional methods, it is more
convenient, easier to be controlled, and consumes less power. With the use of ultrasound
irradiation, a large number of organic reactions can be carried out in milder conditions
with shorter reaction time and higher product yields61. Ultrasound irradiated and
amidosulfonic acid (NH2SO3H) catalyzed synthesis of 3,4-dihydropyrimidi-2-(1H)ones
have reported by Ji-Taai Li and co-workers62 using aldehydes, â-ketoester and urea.
Chenjiang Liu et al.63 have synthesized a novel series of 4-substituted pyrazolyl-
3,4-dihydropyrimidin-2(1H)-thiones under ultrasound irradiation using magnesium
perchlorate [Mg(ClO4)2] as catalyst, by the condensation of 5-chloro/phenoxyl-3-methyl-
1-phenyl-4-formylpyrazole, 1,3-dicarbonyl compound and urea or thiourea in moderate
yields. The catalyst exhibited remarkable reactivity and can be recycled.
Sonication of aromatic aldehydes, urea and ethyl acetoacetate in presence of
solvent (ethanol) or solvent-less dry media (bentonite clay) by supporting-zirconium
chloride (ZrCl4) as catalyst at 35 kHz gives 6-methyl-4-substitutedphenyl-2-oxo-1,2,3,4-























Where X = O/S





In 1893 Biginelli reported the first synthesis of dihydropyrimidines by a simple
one-pot condensation reaction of ethyl acetoacetate, benzaldehyde and urea65.
Despite the importance and current interest in dihydropyrimidines of the Biginelli
type, the mechanism of the classical three-component Biginelli condensation has not
been elucidated with certainty66. Early work by Folkers and Johnson67 suggested that
N,N’-benzylidienebisurea (i.e. the primary bimolecular condensation product of









































































In 1973 Sweet and Fissekis proposed that a “carbenium ion mechanism”,
produced by acid-catalyzed aldol reaction of benzaldehyde with ethyl acetoacetate, is
the key intermediate and is formed in the first and limiting step of the Biginelli reaction68.
Kappe C. O.69 carried out a detailed reinvestigation of the mechanism of the
Biginelli condensation using 1H NMR and 13C NMR spectroscopy to identify possible
intermediates.
Kappe C. O. has established that the key step in this sequence involves the acid
catalyzed formation of an N-acyliminium ion intermediate of (5) from the aldehyde (2)
and urea (3) precursors. Interception of the iminium ion (5) by ethyl acetoacetate (1),
presumably through its enol tauter, produces an open chain ureide (7) which subsequently
cyclized to hexahydropyrimidine (10). Acid-catalyzed elimination of water from (10)
ultimately leads to the final DHPM product (11). The reaction mechanism can therefore




































4-Aryl-1,4-dihydropyridines (DHPs)  of the nifedipine type e.g. nifedipine are
the most studied class of organic calcium channel modulators. More than 30 years after
the introduction of nifedipine (12), many DHP analogs have now been synthesized and
numerous second-generation commercial products have appeared in the market e.g.
nitrendipine, nicardipine and amlodipine71. The aza-analogs such as dihydropyrimidines
(13) which show a very similar pharmacological profile to classical dihydropyridine calcium
channel modulators72-76. Over the past several lead-compounds were developed e.g.















































































antihypertensive activity to classical dihydropyridine drugs and compare favorable with
second-generation analogs such as amlodipine and nicardipine73.
Calcium ion plays a vital role in a large number of cellular processes, including
excitation-contraction and stimulus-secretion77,78. The regulation of the intracellular
concentration of this ion makes possible the control of such Ca2+ dependent processes.
One means of accomplishing this is by the use of agents known as calcium channel
antagonists, which inhibit the movement of calcium through certain membrane channel79-81.
K. S. Atwal82 prepared the 2-heterosubstituted-4-aryl-l,4-dihydro-6-methyl-5
pyrimidinecarboxylic acid esters (15), which lack the potential C3 symmetry of
dihydropyridine calcium channel blockers, were prepared and evaluated for biological
activity. Biological assays using potassium-depolarized rabbit artery and radioligand
binding techniques showed that some of these compounds are potent mimics of
dihydropyridine calcium channel blockers. The combination of a branched ester e.g.
isopropyl, sec-butyl and an alkylthio group e.g. SMe was found to be optimal for
biological activity. Dihydropyrimidines (15) were found to be 30 fold less active than
dihydropyridines. The solid-state structure of dihydropyrimidine analogue (16) shows



































that these compounds can adopt a molecular conformation which is similar to the reported
conformation of dihydropyridine calcium channel blockers.
K. Atwal et al.83 synthesized the 3-substituted 1,4-dihydropyrimidine (17) and
documented that vasorelaxant activity was critically dependent on the size of the C5
ester group, isopropyl ester being the best, a variety of substituents (carbamate, acyl,
sulfonyl, alkyl) were tolerated at N3. The dihydropyrimidines (17) are significantly more
potent than corresponding 2-heteroalkyl-l,4-dihydropyrimidines. Dihydropyridine
enantiomer usually show 10-15 fold difference in activity, while the enantiomers of
dihydropyrimidine (18) show more than a 1000 fold difference in activity. These results
strengthen the requirement of an enamino ester for binding to the dihydropyridine receptor
and indicate a nonspecific role for the N3-substituent.
George C. Rovnyak et al.84 examined a series of novel dihydropyrimidine calcium
channel blockers that contain a basic group attached to either C5 or N3 of the heterocyclic



































(19a) (R) and (19b) (S) were synthesized. Dihydropyrimidine (19a) is equipotent to
nifedipine and amlodipine in vitro .  In the spontaneously hypertensive rat,
dihydropyrimidine (19a) is more potent and longer acting than nifedipine and compares
most favorably with the long-acting dihydropyridine derivative amlodipine.
Dihydropyrimidine (19a) has the potential advantage of being a single enantiomer.
Selma Sarac and co-workers85,86 have synthesized 4-arlyl-3,4-dihydropyrimidin-
2(1H)-one/thione derivatives. The calcium channel blocker activities of all compounds
performed on isolated rat ileum. Product (20), 2-nitrophenyl derivative and (21), 2-
bromophenyl derivative have potent antispasmodic activity on BaCl2 stimulated rat ileum.
N. Dhanapalan and co-workers87 have synthesized dihydropyrimidinones and
describe compound (22) have a high binding affinity (Ki = 0.2nM) for á 1a receptor and
greater than 1500 fold selectivity over á 1b and á1d adreno receptors. Modification of the
linker in (22) gave compounds (23) and (24)88 viz μ-opioid receptor. Both these
compounds showed good á 1a binding affinity (Ki = 0.2nM) and selectivity (>800-fold
over á 1b and á 1d), also showed good selectivity over several other recombinant human
G-protein coupled receptors. They have also identified that compound (25)89 was a
lead compound with a binding and functional profile comparable to that of (22). 25 have
































The synthesis and differential antiproliferative activity of monastrol (26a),
oxomonastrol (26b) and eight oxygenated derivatives (28a,b–31a,b) on seven human cancer
cell lines are described by Dennis Russowsky90. For all evaluated cell lines, monastrol
(26a) was shown to be more active than its oxo-analogue, except for HT-29 cell line,
suggesting the importance of the sulfur atom for the antiproliferative activity. Monastrol
(26a) and the thio derivatives (28a, 29a) and (31a) displayed relevant antiproliferative
properties with 3,4-methylenedioxy derivative (31a) being approximately more than 30

















































































26a X = S Monastrol 27a X = S 28a X = S
26b X = O Oxo-monastrol 27b X = O 28b X = O
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Y. Mizutani and co-workers91,92 identify that dihydropyrimidine dehydrogenase
(DPD) is the rate-limiting enzyme in the pathway of uracil and thymine metabolism. DPD
is also the principle enzyme involved in the degradation of 5-fluorouracil and anticancer
chemotherapeutic agent that is used clinically to treatment of bladder cancer and renal
cell carcinoma.
NEW MOLECULES UNDER CLINICAL STUDY
Many new molecules which are under study from phase-I to phase-IV clinical
trials for different pharmacological action have shown that the basic characteristic of
morpholine to behave as hidden amine has attracted many medicinal chemists to
incorporate this feature in drug design. Some interesting compounds are as under.
Treatment of Hypertension Calcium Channel Blokers
Calcium Channel Blockers Company Name: Merck & Co.
































29a X = S
29b X = O
30a X = S
30b X = O
31a X = S


















Moreover one compound (33) is very active against non-nucleoside inhibitor of
human hepatitis B virus (IC50 = 53 nM for reduction of HBV DNA in human hepatoma
HepG2.2.15 cells) with low cytotoxicity in uninfected cells (CC50 = 7 mcM). Compound
inhibited both viral DNA and viral cores in HepG2.2.15 cells and HBV-transfected cell
lines, whereas it did not affect the activity of endopolymerase and had no effect on other
DNA or RNA viruses. In vivo in a transgenic mouse model, oral doses of 3-100 mg/kg
b.i.d. or t.i.d. for up to 28 days dose-dependently.
Decreased viral DNA in the liver and plasma with efficacy comparable to
lamivudine. However, unlike lamivudine, compound reduced cytoplasmic HBV core
antigen (HBcAg) in the liver of mice. Pharmacokinetic studies in mice showed rapid
absorption, 30 % bioavailability and dose-proportional plasma levels.
Compound Code: Bay-41-4109 Calcium Channel Blocker
Anti Hepatities B Virus Drugs Drug Data Report, 8(5), 465 (1986).
Bayer
Drug Data Report, 24(2), 165 (2002).
Leukotrine Antagonist    Calcium Channel Blocker












































Antifungal Agent Antimalarial Agent
Clin Microbiol Infect, 9, 1504 (2003). Iancet, 361 (9357), 577 (2003).
In vitro susceptibility of Candida species isolated from cancer patients against
some antifungal agents.
Acute Myocardial Infection Immunosuppressants
Treatment of Antiplatlet Therapy Oncolytic Drug
Antibacterial Drugs Anti HIV Agent
39th Intersci Conf Antimicrob Agents Chemother Reverse Transcripase Inhibitors
(Sept 26-29, San Francisco) 1999, Abst F1808 Non-nucleoside HIV-1 reverse
In vitro activity of novel 6-anilinouracils targeted transcriptase inhibitor, Compound
to DNA polymerase. was active not only against wild-type
HIV-1 strains (IC50 = 3 nM against






















































CATALYTIC STUDY OF MOLECULAR IODINE
Due to some limitations of Biginelli method and strong acidic conditions94, there
are several efficient methods developed for the synthesis of 1,4-DHPMs, which comprise
the use of Silica triflate95, Iodotrimethylsilane in acetonitrile96, Strontium(II)nitrate97,
PEG-400098, chloroacetic acid99, InBr3
100, microwave101,102, KSF montmorillonite103 etc
as catalysts. However, the use of high temperatures, expensive metal precursors and
longer reaction times are limits of these methods. Due to these problems, the development
of an efficient and versatile method for the synthesis of 1,4-DHPMs is an interesting
research area and there is a scope for further improvement towards mild reaction
conditions and to improve the yields of the reaction.
Molecular iodine has attracted attention as an inexpensive, readily available catalyst
for various organic transformations104 to afford the corresponding products in excellent
yields with high selectivity. It has been used as a mild Lewis acid in the dehydration of
tertiary alcohols to alkenes, in the formation of ethers, as well as â-keto enol ethers105,
for esterification106, transesterification107, acetylation108 and benzothiophene109 formation,
but there are only few reports about its use for the synthesis of DHPMs110.
Therefore, it is worthwhile to synthesize some new 1,4-DHPMs from three-
components domino reaction promoted by a catalytic amount of molecular iodine under
mild reaction conditions. Iodine has been used as a mild Lewis acid and may play a
crucial role in accelerating the dehydrative steps and enolization of 1,3-diketone
compounds. The present methodology offers very attractive features such as short
reaction time, milder reaction condition and good to excellent product yields and
commercially available iodine as a powerful catalyst for the synthesis for one pot multi-
component condensation reactions.
A simple, inexpensive and efficient one-pot synthesis of 1,4-dihydropyridine
derivatives at  room temperature using catalytic amount of iodine were reported by R.
S. Varma et al111  with excellent product yields.
REACTION MECHANISM
In accord with the literature, mechanism of the formation of DHPMs112 and role
of iodine as a catalyst113, it is possible in our reaction that iodine catalyzes the reaction
as a mild Lewis acid. The mechanism proposed by our group120 is shown below. In the
presence of iodine, 1,3-diketone 2 is in equilibrium with the enol form (I). The enol
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immediately attacks the iodine-activated N-acylinium ion (II) intermediate generated
from the reaction of (1) and (3) to form intermediate (III), which then undergoes an
intramolecular cyclization to give (IV). The subsequent dehydration of (IV) results in
dihydropyrimidine (V).
Work done from our laboratory
Synthesis anticancer, antitubercular and antimicrobial activity of some new
pyrimidine derivatives (37) have been reported by K. S. Nimavat112, some new
thiopyrimidine and oxopyrimidine heterocycles (38) bearing 4-(methylsulfonyl)phenyl
nucleus as potent antitubercular and antimicrobial agents was developed and reported
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by D. J. Paghdar113. M. R. Patel114 have reported synthesis and evaluation of
pharmacological activity of some new aminopyrimidine and thiopyrimidine derivatives.
J. D. Akbari and coworkers115 has reported following new series and activities
of some new DHPM’s synthesis of some new 1,2,3,4-tetrahydropyrimidine-2-ones and
their thiazolo[3,2-a]pyrimidine derivatives (38) as a potential biological agents. Synthesis
of some new pyrazolo[3,4-d]pyrimidines and thiazolo[4,5-d]pyrimidines116 (39) and
evaluation of their antimicrobial activities. Green chemistry approach117 to synthesis of
some new trifluoromethyl containing tetrahydropyrimidines under solvent free conditions.
Synthesis and antimicrobial activities of some new pyrazolo[3,4-d]pyrimidines and
thiazolo[4,5-d]pyrimidines118.
M. J. Ladani119 reported synthesis and biological study of oxopyrimidines and
thiopyrimidines (40) of 2-(2,4-dichlorophenyl)imidazo[1,2-a]pyridin-3-carbaldehyde,
multi-component synthesis of dihydropyrimidines (41) by iodine catalyst at ambient



















































  In the past years, considerable evidence has been accumulated to demonstrate
the pharmacodynamic and chemotherapeutic activities of tetrahydropyrimidine derivatives.
To further evaluate the potential of such type of compounds, the synthesis have been
carried out which have been described as under.
SECTION-I: SYNTHESIS OF N-(4-CHLOROPHENYL)-1,2,3,4-TETRAHYDRO
-6-ISOPROPYL-4-ARYL-2-OXO/THIOXOPYRIMIDINE-5-
CARBOXAMIDES USING CONVENTIONAL METHOD AND
MOLECULAR IODINE AS CATALYST AND BIOLOGICAL
SCREENING.
SECTION-II:SYNTHESIS AND BIOLOGICAL SCREENING OF N-(4-
CHLOROPHENYL)-3-FORMYL-6-ISOPROPYL-2-OXO-4-ARYL-
1,2,3,4-TETRAHYDROPYRIMIDINE-5-CARBOXAMIDES.
SECTION-III:SYNTHESIS AND BIOLOGICAL SCREENING OF N-(4-
CHLOROPHENYL)-3-FORMYL-6-ISOPROPYL-2-THIOXO-4-





using conventional method and molecular






SYNTHESIS OF N - (4-CHLOROPHENYL)-1,2 ,3 ,4-TETRAHYDRO-6-
ISOPROPYL-4-ARYL-2-OXO/THIOXOPYRIMIDINE-5-CARBOXAMIDES
USING CONVENTIONAL METHOD AND MOLECULAR IODINE AS
CATALYST AND BIOLOGICAL SCREENING.
The constitution of the synthesized compounds have been characterized by using
elemental analysis, Infrared, 1H Nuclear Magnetic Resonance spectroscopy and further
supported by mass spectroscopy.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards A. Niger at a concentration of 40 μg/ml. The biological

























































Melting points of all the synthesized compounds were taken in open capillary
bath on controlled temperature heating mental. The crystallization of all the compounds
was carried out in appropriate solvents. TLC was carried out on silica gel-G as stationary
phase. 40 % Ethyl acetate in Hexane was used as a mobile phase.
[A] Preparation of N-(4-Chlorophenyl)-4-methyl-3-oxopentanamide.
A suspension of methylisobutryl acetate (0.01 mol, 1.44 ml) and 4-choloroaniline
(0.01 mol, 1.27 gm) in toluene (50 ml) containing catalytic amount of NaOH solution
(0.05 ml, 40 %) was refluxed on oil bath for 8 hr. After completion of the reaction (TLC
monitoring) the solvent was removed under reduced pressure, separated solid was filtered
and washed with petroleum ether and crystallized from ethanol to give analytically pure
product. M. P. 114 °C, Yield 67 %, Calcd. C, 60.13%; H, 5.89%; N, 5.84% for C,
60.04%; H, 5.98%; N, 5.78%.
Classical Method
[B] General procedure for the preparation of N-(4-Chlorophenyl)-1,2,3,4-
tetrahydro-6-isopropyl-4-aryl-2-oxo/thioxopyrimidine-5-carboxamides
The warm mixture of N-(4-chlorophenyl)-4-methyl-3-oxopentanamide (0.01 mol,
2.39 gm), substituted benzaldehyde (0.01 mol) and urea/thiourea (0.01 mol) in ethanol
(15 ml), containing 0.4 ml of concentrated HCl was heated under reflux for 18-24 hr.
After completion of the reaction, the reaction mixture was allowed to stand at RT for
several hours and precipitation was obtained. The product was filtered, washed with
chilled methanol and isolated product crystallized from suitable solvent. The physical





General procedure for the preparation of N-(4-Chlorophenyl)-1,2,3,4-tetrahydro-
6-isopropyl-4-aryl-2-oxo/thioxopyrimidine-5-carboxamides using molecular iodine
as a catalyst
A mixture of substituted benzaldehyde (0.01 mole), N-(4-chlorophenyl)-4-
methyl-3-oxopentanamide (2.39 gm, 0.01 mole), urea/thiourea (0.01 mole) and iodine
(0.38 gm, 1.5 mmole) was charged in a round bottom flask containing ethanol (10 ml).
The reaction mixture was then stirred at room temperature until the reaction was
completed (4-5 hr monitored by TLC). The reaction mixture was treated with aq.
Na2S2O3 solution, extracted into ethyl acetate (2 × 20 ml). The solvent was removed in
vacuo and the resulting crude product was crystallized from the suitable solvent to give
the analytically pure product. The physical constants of the product are recorded in
Table-7a and 8a.
[C] Biological screening of N-(4-Chlorophenyl)-1,2,3,4-tetrahydro-6-isopropyl-
4-aryl-2-oxo/thioxopyrimidine-5-carboxamides
Antimicrobial testing was carried out as described in Part-A, Part-1, Section-I,
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Table-8a: Physical constants of N-(4-Chlorophenyl)-1,2,3,4-tetrahydro-6-
isopropyl-4-aryl-2-thioxopyrimidine-5-carboxamides
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Instrument: Shimadzu FTIR-8400 using KBr DRS techniques. The percentage transmittance is 
given in cm-1 and frequency range is between 400-4000cm-1. 
Type Vibration Mode Frequency cm-1
Alkane -CH3
C-H str. (asym.) 2934
C-H str. (sym.) 2835
C-H i.p.d (asym) 1471
C-H o.o.d (sym) 1398
Aromatic
C-H str. 2996
C=C (skeleton) 1518, 1591
C-H  i.p. bending 1029
C-H o.p bending 851
Carbonyl -C=O 1681, 1657
Amine -NH str. 3285
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Instrument: Shimadzu FTIR-8400 using KBr DRS techniques. The percentage transmittance is 
given in cm-1 and frequency range is between 400-4000cm-1. 
 
Type Vibration Mode Frequency cm-1
Alkane -CH3
C-H str. (asym.) 2935
C-H str. (sym.) 2833
C-H i.p.d (asym) 1483




C-H  i.p. bending 1030
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of Protons Multiplicity Inference
J value in
Hz
1 1.53 3H singlet -CH(CH3)2 -
2 1.72 3H singlet -CH(CH3)2 -
3 3.94 1H singlet -CH(CH3)2 -
4 5.18-5.19 1H doublet -Ha 4.52
5 7.27-7.29 2H dd Ar-Hb,b' 9.8 & 2.9
6 7.54-7.58 2H multiplet Ar-H -
7 7.59-7.63 2H dd Ar-Ha,a' 9.9 & 2.9
8 8.12-8.14 1H doublet Ar-H 8.1
9 8.27 1H singlet Ar-H -
10 8.45 1H singlet -NH -
11 9.03 1H doublet -NH 4.64
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of Protons Multiplicity Inference
J value
in Hz
1 1.53 3H singlet -CH3 -
2 1.54 3H singlet -CH3 -
3 3.83 1H singlet -CH -
4 5.05-5.06 1H doublet chiral-H 4.52
5 7.23-7.74 9H multiplet Ar-H -
6 8.32 1H singlet -NH -
7 8.83 1H singlet -NH -







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































SYNTHESIS AND BIOLOGICAL SCREENING OF N-(4-CHLOROPHENYL)-
3-FORMYL-6-ISOPROPYL-2-OXO-4-ARYL-1,2 ,3 ,4-TETRAHYDRO-
PYRIMIDINE-5-CARBOXAMIDES.
Much interest has been focused around dihydropyrimidinone derivatives because
of their wide variety of pharmacological properties and industrial applications. In view
of these findings and achieve to better drug potency, we have synthesized N-(4-
chlorophenyl)-3-formyl-6-isopropyl-2-oxo-4-aryl-1,2,3,4-tetrahydropyrimidine-5-
carboxamides by the formylation of N-(4-chlorophenyl)-6-isopropyl-2-oxo-4-aryl-
1,2,3,4-tetrahydropyrimidine-5-carboxamides at low temperature.
The constitution of the synthesized compounds have been characterized by using
Elemental analysis, Infrared, 1H Nuclear Magnetic Resonance spectroscopy and further
supported by mass spectroscopy.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards A. Niger at a concentration of 40 μg/ml. The biological



























Melting points of all the synthesized compounds were taken in open capillary
bath on controlled temperature heating mental. The crystallization of all the compounds
was carried out in appropriate solvents. TLC was carried out on silica gel-G as stationary
phase. 30 % Ethyl acetate in Hexane was used as a mobile phase.
[A] General procedure for the preparation of N-(4-Chlorophenyl)-1,2,3,4-
tetrahydro-6-isopropyl-4-aryl-2-oxo/thioxopyrimidine-5-carboxamides
using molecular iodine as a catalyst
See Part-C, Section-I, Experimental Section [B], Catalytic method.
[B] General procedure for the preparation of N-(4-Chlorophenyl)-3-formyl-6-
isopropyl-2-oxo-4-aryl-1,2,3,4-tetrahydropyrimidine-5-carboxamides.
To a solution of N-(4-Chlorophenyl)-6-isopropyl-2-oxo-4-aryl-1,2,3,4-
tetrahydropyrimidine-5-carboxamide (0.01 mole) in 10 ml of dry DMF, POCl3 (0.01
mole) was added under stirring in an ice bath. The resulting solution was heated at
70 °C for 40 minutes and then was poured into 150 ml of ice water. The product was
filtered and washed with chilled methanol and isolate as crystalline powder. The physical
constants of the product are recorded in Table-9a.
[C] Biological screening of N-(4-Chlorophenyl)-3-formyl-6-isopropyl-2-oxo-4-
aryl-1,2,3,4-tetrahydropyrimidine-5-carboxamides.
Antimicrobial testing was carried out as described in Part-A, Part-1, Section-I,
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Instrument: Shimadzu FTIR-8400 using KBr DRS techniques. The percentage transmittance is 
given in cm-1 and frequency range is between 400-4000cm-1. 
Type Vibration Mode Frequency cm-1
Alkane -CH3
C-H str. (asym.) 2996
C-H str. (sym.) 2852
C-H i.p.d (asym) 1450
C-H o.o.d (sym) 1399
Aromatic
C-H str. 3164
C=C (skeleton) 1527, 1596
C-H  i.p. bending 1017
C-H o.p bending 857
Aldehyde -C-H 2794, 2852
Carbonyl -C=O 1708
Carbonyl -C=O 1691
Amine -NH str. 3350
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of Protons Multiplicity Inference
J value
in Hz
1 1.61 3H singlet -CH(CH3)2 -
2 1.79 3H singlet -CH(CH3)2 -
3 4.19 1H singlet -CH(CH3)2 -
4 6.00 1H singlet -Ha -
5 7.19-7.32 5H multiplet Ar-H -
6 7.53-7.60 3H multiplet Ar-H -
7 9.6 1H singlet(b) -N-H -
8 9.86 1H singlet(b) -N-H -
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































SYNTHESIS AND BIOLOGICAL SCREENING OF N-(4-CHLOROPHENYL)-
3-FORMYL-6-ISOPROPYL-2-THIOXO-4-ARYL-1,2,3,4-TETRAHYDRO-
PYRIMIDINE-5-CARBOXAMIDES.
Compounds containing pyrimidine ring are widely distributed in nature. Many of
these derivatives are reported to possess different biological activities. In view of these
reports, we have synthesized N-(4-chlorophenyl)-3-formyl-6-isopropyl-2-thioxo-4-aryl-
1,2,3,4-tetrahydropyrimidine-5-carboxamides by the formylation of N-(4-chlorophenyl)-
6-isopropyl-2-thioxo-4-aryl-1,2,3,4-tetrahydropyrimidine-5-carboxamides.
The constitution of the synthesized compounds have been characterized by using
elemental analysis, Infrared, 1H Nuclear Magnetic Resonance spectroscopy and further
supported by mass spectroscopy.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards A. Niger at a concentration of 40 μg/ml. The biological




























Melting points of all the synthesized compounds were taken in open capillary
bath on controlled temperature heating mental. The crystallization of all the compounds
was carried out in appropriate solvents. TLC was carried out on silicagel-G as stationary
phase. 30 % Ethyl acetate in Hexane was used as a mobile phase.
[A] General procedure for the preparation of N-(4-Chlorophenyl)-1,2,3,4-
tetrahydro-6-isopropyl-4-aryl-2-oxo/thioxopyrimidine-5-carboxamides
using molecular iodine as a catalyst
See Part-C, Section-I, Experimental Section [B], Catalytic method.
[B] General procedure for the preparation of N-(4-Chlorophenyl)-3-formyl-6-
isopropyl-2-thioxo-4-aryl-1,2,3,4-tetrahydropyrimidine-5-carboxamides.
To a suspension of N-(4-Chlorophenyl)-6-isopropyl-4-aryl-2-thioxo-1,2,3,4-
tetrahydropyrimidine-5-carboxamide (0.01 mole) in dry DMF (15 ml), POCl3 (3.06 ml,
0.02 mole) was added under stirring in an ice bath. Stirring was continued at room
temperature for another 20 minute and then solution was poured into 200 ml ice water.
The product was filtered and washed with chilled methanol and isolated as crystalline
powder. The physical constants of the product are recorded in Table-10a.
[C] Biological screening of N-(4-Chlorophenyl)-3-formyl-6-isopropyl-2-thioxo-
4-aryl-1,2,3,4-tetrahydropyrimidine-5-carboxamides.
Antimicrobial testing was carried out as described in Part-A, Part-1, Section-I,
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Instrument: Shimadzu FTIR-8400 using KBr DRS techniques. The percentage transmittance is 
given in cm-1 and frequency range is between 400-4000cm-1. 
Type Vibration Mode Frequency cm-1
Alkane -CH3
C-H str. (asym.) 2980
C-H str. (sym.) 2847
C-H i.p.d (asym) 1459




C-H  i.p. bending 1089
C-H o.p bending 820
Aldehyde -C-H 2766, 2847
Carbonyl -C=O 1701
Amine -NH str. 3235












Studies on Heterocyclic…  190 
Pyrimidine Derivatives… 











of Protons Multiplicity Inference
J value
in Hz
1 1.55 3H singlet -CH(CH3)2 -
2 1.75 3H singlet -CH(CH3)2 -
3 3.78 3H singlet -OCH3 -
4 4.19 1H singlet -CH(CH3)2 -
5 5.91 1H singlet -He -
6 6.82-6.86 2H dd Ar-Ha,a' 6.8 & 1.9
7 7.14-7.17 2H dd Ar-Hc,c' 8.7 & 2.1
8 7.24-7.27 2H dd Ar-Hb,b' 6.8 & 1.9
9 7.54-7.60 2H dd Ar-Hd,d' 8.8 & 2.0
10 9.75 1H singlet(b) -N-H -
11 9.97 1H singlet(b) -N-H -
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Pyrazolines (1) have attracted attention of medicinal chemists for both with regard
to heterocyclic chemistry and the pharmacological activities associated with them.
Amongst nitrogen containing five membered heterocycles, pyrazolones (2) have proved
to be the most useful framework for biological activities. The pharmaceutical importance
of these compounds lies in the fact that they can be effectively utilized as antibacterial,
antifungal, antiviral, antiparasitic, antitubercular and insecticidal agents. In 1967 Jarboe,
reviewed the chemistry of pyrazolines, which have been studied extensively for their
biodynamic behaviour and industrial applications.
As evident from the literature in recent years a significant portion of research
work in heterocyclic chemistry has been devoted to pyrazoles containing different alkyl,
aryl and heteroaryl groups as substituents.
SYNTHETIC ASPECT
See Part-B, Section II, Synthetic Aspect
THERAPEUTIC IMPORTANCE
See Part-B, Section II, Therapeutic Importance
Looking to the diversified biological activities we have synthesized some pyrazole
derivatives in order to achieving better therapeutic agents. These studies are described
in following section.
SECTION-I: SYNTHESIS CHARACTERIZATION AND X-RAY














SYNTHESIS CHARACTERIZATION AND X-RAY CRYSTALLOGRAPHIC
STUDY OF 1-PHENYL-3-METHYLPYRAZOLE-2-EN-5-ONE.
Pyrazole derivatives represent one of the most active class of compounds having
a wide spectrum of biological activities. Looking to the interesting properties of pyrazoles
it was considered worthwhile to synthesize a pyrazole for obtaining biologically potent
agents.
The constitution of the synthesized compound have been characterized by using
Infrared, mass spectroscopy and further supported by X-Ray crystallographic study.
EXPERIMENTAL SECTION
[A] Preparation of 1-Phenyl-3-methylpyrazole-2-en-5-one (PMP)
A mixture of Ethyl acetoacetate (0.01 mole) and phenyl hydrazine (0.01 mole) in
methanol (10 ml) is taken in a clean dry RBF. To this reaction mixture 2 drops of acetic
acid were added and the solution was reflux for 5 hrs in water bath. After completion of
the reaction (TLC monitoring), the solvent was removed under reduced pressure,
separated solid was filtered, and resulting solid was crystallized from methanol to give
analytically pure product. M. P. 124-126 °C, (Reported1 127 °C) Yield 77 %.
[B] Growth and Characterization of 1-Phenyl-3-methylpyrazole-2-en-5-one
(PMP) crystal:
N-Phenyl, especially N-phenyl pyrazoline finds applications in building blocks
for the synthesis of chiral compounds2. Due to the medicinal properties of pyrazoline
derivatives, the crystal growth of organic material 1-Phenyl-3-methylpyrazole-2-en-5-













[C] Growth of 1-Phenyl-3-methylpyrazole-2-en-5-one (PMP) crystals:
In the present study, methanol were selected as solvent, however, methanol
yielded good quality single crystals. The seed crystals were grown from controlled
evaporation of saturated solution of PMP in methanol and good quality crystals were
picked up for growth. A glass jar of 4 cm diameter and 7 cm length was selected as a
crystallizer. This jar was kept in a water bath with temperature control of ±  0.1 °C.
Water in the bath was stirred slowly. Supersaturated solution of PMP was poured into
crystallizer and a seed crystal was hung by using very fine nylon thread. The temperature
of the water bath was maintained at 40 °C and the evaporation rate was carefully
controlled.
Figure [1]: Photograph of the grown PMP crystals
Good quality single crystals with maximum dimension 1.5 cm X 0.75 cm were
obtained. Figures [1] show the types of crystals grown. The crystals were yellowish in
color.
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Instrument: Shimadzu FTIR-8400 using KBr DRS techniques. The percentage transmittance is 
given in cm-1 and frequency range is between 400-4000cm-1. 
 
Type Vibration Mode Frequency cm-1
Alkane -CH3
C-H str. (asym.) 2962
C-H str. (sym.) 2865
C-H i.p.d (asym) 1446




C-H  i.p. bending 1089
C-H o.p bending 820
Pyrazole ring
=N-N- str. 1172






















































































Single crystal X-ray Diffraction analysis
Single crystal X-ray diffraction is the most common experimental method of
obtaining a detailed picture of a small molecule that allows resolution of individual atoms.
It is performed by analyzing the diffraction of x-rays from an ordered array of many
identical molecules. Many molecular substances, including proteins, polymers and other
solidify in to crystals under the proper conditions. When solidifying in to the crystalline
state, these individual molecules typically adapted as one of only a few possible
orientations. A crystal is a three dimensional array of those molecules that are held together
by Van der Waals and noncovalent bonding. The smallest representative unit of this
crystal is referred to as the unit cell. Understanding the unit cell of these arrays simplifies
the understanding of a crystal as a whole.
Characterization of PMP crystals
Single Crystal X-ray Diffraction and Structure Determination
The three dimensional intensity data were collected on an Enraf-Nonius CAD-4
diffractometer. The reflection data were collected at 293 K and ù /2è scan mode was
employed for data collection by using MoKá radiation (ë = 0.71073 Å). The structure
has been elucidated by direct methods using SHELEX 973. All non-hydrogen atoms of
the molecule were located from the E-map. Isotropic refinement of the structure by
least squares methods using SHELEX 974 was followed by anisotropic refinement of all
the non-hydrogen atoms. All the hydrogen atoms were fixed stereochemically. Atomic
scattering factors were taken from International tables for crystallography (1992 Vol. C
Tables 4.2.6.8 and 6.1.1.4). Geometrical and other structural calculations were performed
by using PARST5 programme. The experimental details and other measurement data are
given in Table [I]. Geometry of intra and intermolecular hydrogen interactions are given
in Table [II]. The bond lengths and bond angles are given in Table [III]. An ORTEP
diagram of the compound with atom numbering scheme is shown in figure [2], unit cell of
the PMP are shown in figure [3] and figure [4] represents the packing diagram of PMP




Figure [2]: ORTEP Diagram of PMP crystals




Table – I: Experimental details and other measurement data of PMP crystal
Crystal data and experimental data 
Chemical Formula C10H10N2O 
Relative Chemical formula weight 174.20 
Crystal system Monoclinic 
Space group P21/c 
Cell dimensions a = 10.205 Å 
 b = 11.096 Å 
 c = 15.679 Å 
Z 8 
V 1767.6 (4) Å3 
T 120 K 
Dx 1.309 mg/m3 
μ 0.82 cm-1 
Recording Range θmax 27° 
Radiation (Mo Ka) λ =0.71073 Å 
Crystal Size 0.3 x 0.3 x  0.2 mm 
F(000) 736 
No. of recorded reflections 2989 
No. of observed reflections 2534 
No. of parameters 315 
R 4.9 % 
Rw 4.7 % 
Refinement method Full-matrix least square on F2 
Measurement ENRAF-NONIUS Detector Programme 
Programme system ENRAF-NONIUS Programme 
Structure Determination SHELXS97 






Table – II: Geometry of intra and inter molecular hydrogen interactions
Table – III: Various bonds and bond length of PMP crystals
N2-H2...N2'( 1) 2.803(.002) 1.971(.002) 162.71( 0.12) 
N2-H2...N1'( 1) 3.806(.002) 2.952(.001) 172.69( 0.11) 
O'-H'...O ( 1) 2.478(.002) 1.705(.001) 156.17( 0.12) 
C10-H10B...O'( 2) 3.482(.004) 2.851(.002)   124.20( 0.19) 
C3-H3...O( 3) 3.531(.004) 2.646(.002)   159.30( 0.20) 
C3-H3...O'( 4) 3.647(.004) 2.908(.002) 137.28( 0.20) 
N2'-H2'...N2( 5) 2.803(.002)    2.034(.002)       148.43( 0.12) 
C10'-H10D...N2( 5) 3.660(.003)    2.925(.002)   134.25( 0.18) 
C1'-H1'...N2( 5) 3.588(.003)     2.968(.002)        125.48( 0.16) 
Equivalent positions: ( 0) x,y,z; ( 1) -x+1,+y-1/2,-z+1/2; ( 2) x,-y-1/2,+z+1/2; ( 3) -
x+2,+y-1/2,-z+1/2; ( 4) x+1,+y,+z; ( 5) -x+1,+y+1/2,-z+1/2. 
 
Bond Lengths (Å) 
O-C(9)                         1.321(3) N(2')-C(7')                   1.344(3) 
N(1)-C(9)                          1.356(2)      N(2')-N(1')                   1.379(2) 
N(1)-N(2)                      1.372(2) O'-C(9')                       1.260(2) 
N(1)-C(6)                      1.415(3) N(1')-C(9')                   1.378(2) 
N(2)-C(7)                      1.318(3) N(1')-C(6')                   1.413(3) 
C(6)-C(1)                      1.381(3) C(9')-C(8')                   1.397(3) 
C(6)-C(5)                      1.382(3) C(6')-C(5')                   1.382(3) 
C(9)-C(8)                      1.366(3) C(6')-C(1')                   1.390(3) 
C(5)-C(4)                      1.381(3) C(7')-C(8')                   1.354(3) 
C(1)-C(2)                      1.385(4) C(7')-C(10')                 1.475(3)   
C(7)-C(8)                   1.402(3) C(1')-C(2')                   1.384(4) 
C(7)-C(10)                     1.487(3) C(5')-C(4')                   1.371(4) 
C(4)-C(3)                      1.370(4) C(2')-C(3')                   1.383(4) 





Bond Angles ( ° ) 
C(9)-N(1)-N(2)               110.07(16) C(7')-N(2')-N(1')         108.31(17) 
C(9)-N(1)-C(6)               129.61(17) C(9')-N(1')-N(2')         108.27(16) 
N(2)-N(1)-C(6)               120.31(15) C(9')-N(1')-C(6')          129.98(17) 
C(7)-N(2)-N(1)               106.13(16) N(2')-N(1')-C(6')         120.53(16) 
C(1)-C(6)-C(5)               120.6(2) O'-C(9')-N(1')              120.80(19) 
C(1)-C(6)-N(1)               118.8(2) O'-C(9')-C(8')              133.32(19) 
C(5)-C(6)-N(1)               120.58(19) N(1')-C(9')-C(8')          105.86(18) 
O-C(9)-N(1)                  120.15(19) C(5')-C(6')-C(1')          119.5(2) 
O-C(9)-C(8)                  132.27(19) C(5')-C(6')-N(1')          120.6(2) 
N(1)-C(9)-C(8)               107.58(17) C(1')-C(6')-N(1')          119.9(2) 
C(4)-C(5)-C(6)               119.2(2) N(2')-C(7')-C(8')          108.71(19) 
C(6)-C(1)-C(2)               118.6(3) N(2')-C(7')-C(10')        119.5(2) 
N(2)-C(7)-C(8)               110.78(19) C(8')-C(7')-C(10')        131.7(2) 
N(2)-C(7)-C(10)              120.8(2) C(7')-C(8')-C(9')          108.66(19) 
C(8)-C(7)-C(10)              128.4(2) C(2')-C(1')-C(6')          119.3(3) 
C(9)-C(8)-C(7)               105.44(18) C(4')-C(5')-C(6')          119.7(2) 
C(3)-C(4)-C(5)               120.7(3) C(3')-C(2')-C(1')          120.9(3) 
C(3)-C(2)-C(1)               121.3(3) C(4')-C(3')-C(2')          118.8(3) 





Figure [4]: Packing diagram 1-Phenyl-3-methylpyrazole-2-en-5-one (PMP)
showing intermolecular hydrogen-bonding network
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